Clinical trial NCT03696342
Conditions: Conjunctivitis, Bacterial
Keywords: pazufloxacin PRO-157 Fluoroquinolones
Sponsor: Laboratorios Sophia S.A de C.V.
Start date: 2018-10-01; Completion date: 2020-03-24
Enrollment: 46 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative group, of parallel groups and randomized. about a ophthalmic topical antibiotic for the treatment of bacterial conjunctivitis.

Goal:To compare the efficacy of the ophthalmic solution of pazufloxacin 0.6%, against the ophthalmic solution of gatifloxacin 0.3%, in the treatment of acute bacterial conjunctivitis.

Hypothesis:the ophthalmic solution PRO-157 is not inferior in the treatment of bacterial conjunctivitis, compared to the ophthalmic solution of gatifloxacin 0.3%, by means of the clinical remission of the disease.

Number of patients:

160 patients, each one will provide an eye for efficacy analysis, divided into 2 groups (80 eyes per group).

Detailed description:
The study subjects will be recruited from various research centers in western and central Mexico.

Each research center has a monitoring plan specified according to the recruitment capabilities of the same, which must be at least once a month, where the queries of your data entered into the electronic case report report will be reported to the center. (e-CRF) for which it has as time limit the next monitoring visit to make the pertinent changes.

The report of adverse events will be made according to the standard operating procedure (PNO) where it specifies, according to Official Mexican Standard 220 (NOM 220), that the signs or symptoms of adverse events will be reported based on the Medical Dictionary. for Regulatory Activities, for which the sponsor has version 20.1 in Spanish. For serious adverse events (SAEs) will be reported in accordance with the standardized operation procedure of pharmacovigilance of the sponsor, which adheres to the guidelines of NOM 220 and international regulations, these will be reported in the regulatory framework to the regulatory entity within a period of time no more than 7 days.

The study is registered in the National Registry of Clinical Trials (RNEC), entity equivalent to Clinical Trials in Mexico.

The quality assurance plan is carried out by the sponsor through the Quality Assurance agent in Clinical Research, whose function is to conduct inspections and audits of the research sites to document and generate reports of deviations from the protocol. In addition to the visits of the monitoring plan, the reliability of the data is guaranteed.

To verify the integrity, veracity and reliability of the data entered into the e-CRF, the monitors of each center will check the information uploaded to the portal with that reported in the source document of the principal investigator (PI), such as clinical notes, clinical history and documents. and formats attached to the research protocol, physical case report format, as well as those provided by the sponsor to the PI (subject's diary and quality and satisfaction survey).

The e-CRF used for this clinical study is provided by an internationally certified provider with the highest quality standards, protection of information under current regulations and confidentiality guarantee. The information that the PIs enter into the e-CRF is collated and verified by the clinical monitors and by the service provider's personnel, later reviewed and approved by the medical ophthalmologist researcher and by the Clinical Security Pharmacologist, who authorize the monitored data of clinical information and safety of the study molecule, respectively.

Arms: arm 1: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic

1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days. arm 2: Gatifloxacin 0.3%. by Allergan, topical ophthalmic

1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.
Interventions: intervention 1: Pazufloxacin intervention 2: Zymar
Intervention descriptions: intervention 1: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic

1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days. intervention 2: Gatifloxacin 0.3%. by Allergan, topical ophthalmic

1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.

Protocol documents:
Prot_SAP_001.pdf: 
 
 
 
 
 
Creation date : february de 2017 
Clinical study of the efficacy of the 
ophthalmic solution of Pazufloxacin 0.6% 
(PRO-157) for the treatment of acute 
bacterial conjunctivitis, compared to the 
ophthalmic solution of Gatifloxacin 0.3%. 
Protocol code : SOPH157-0217/III 
Protocol version : 2 
Date of the version : 19/01/2018 
Registry :  Pending  
Sponsor :  Sophia Laboratories, S.A. of C.V. 
 


 
 
 
 
 Page left intentionally blank


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 3 of 59 
 
1. Summary 
Title of the study: 
Clinical study of the efficacy of the ophthalmic solution of Pazufloxacin 0.6% (PRO-157) for the 
treatment of acute bacterial conjunctivitis, compared to the ophthalmic solution of Gatifloxacin 
0.3%. 
 
Protocol code:SOPH157-0217/III 
Creation date: 27/02/2017 
Protocol version: 2.0 
Date of the version: 19/01/2018 
Therapeutic indication: 
Ophthalmic topical antibiotic for the treatment of bacterial conjunctivitis. 
Study period: 
18 months 
Development phase:  
III 
Goals: 
To compare the efficacy of the ophthalmic solution of pazufloxacin 0.6%, against the ophthalmic 
solution of gatifloxacin 0.3%, in the treatment of acute bacterial conjunctivitis. 
Hypothesis: 
The ophthalmic solution PRO-157 is not inferior in the treatment of bacterial conjunctivitis, 
compared to the ophthalmic solution of gatifloxacin 0.3%, by means of the clinical remission of 
the disease. 
Methodology: 
Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative group, of 
parallel groups and randomized. 
Number of patients: 
160 patients, each one will provide an eye for efficacy analysis. 
160 eyes divided into 2 groups (80 eyes per group). 
Diagnosis and main inclusion criteria: 
Diagnosis: Acute bacterial conjunctivitis. 
Main criteria: 
- 
Informed consent 
-            Age ≥ 1 year 
- 
Both genders 
-              Clinical picture of acute bacterial conjunctivitis defined by: 
º Conjunctival secretion 
º or bulbar conjunctival hyperemia 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 4 of 59 
 
 
Test product, dose and route of administration: 
• PRO-157. Pazufloxacin 0.6%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, 
Mexico. 
- Dosage: 1 drop, 3 times a day during the waking period in both eyes (at approximate 
intervals of 6 hours), for 7 days. 
- 
 Route of administration: topical ophthalmic 
Treatment duration: 
7 days 
Reference product, dose and route of administration, batch: 
1. Zymar®. Gatifloxacin 0.3%. Prepared by Allergan, S.A. of C.V. 
- Dosage: 1 drop, 3 times a day during the waking period in both eyes (at approximate 
intervals of 6 hours), for 7 days. 
- Route of administration: topical ophthalmic 
Evaluation criteria: 
Effectiveness: 
• Primary 
         º Clinical remission of acute bacterial conjunctivitis on day 8, absence of: 
- Conjunctival secretion 
- Bulbar conjunctival hyperemia 
• Secondary 
o Bacterial eradication, on day 8, in the cultures of patients with positive basal cultures. 
o Degree of conjunctival hyperemia during visits 
o Degree of conjunctival secretion during visits 
o Overall researcher's rating of clinical changes and symptoms during visits 
Security: 
• 
Adverse events (EA) 
Statistical methodology: 
The result of the continuous quantitative variables will be presented in measures of central 
tendency. 
The normal distribution of the results will be obtained through the Kolmogorov-Smirnov and 
Shapiro-Wilks test. The statistical analysis of the continuous quantitative variables to find 
significant differences (p) will be in the analysis between groups: t test for independent groups.   
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 5 of 59 
 
2. Content. 
1. SUMMARY 
3 
2. CONTENT 
5 
3. ABBREVIATION INDEX 
9 
4. ADMINISTRATIVE STRUCTURE OF THE STUDY 
11 
5. INTRODUCTION 
13 
5.1 THEORETICAL FRAMEWORK 
13 
5.1.1 THEORETICAL FRAMEWORK 
13 
5.1.2 CLINICAL PICTURE OF ACUTE BACTERIAL CONJUNCTIVITIS 
14 
5.1.3 TREATMENT OF ACUTE BACTERIAL CONJUNCTIVITIS 
14 
5.2 DEFINITION OF THE PROBLEM AND FUNDAMENTAL REASON 
15 
5.3 BACKGROUND 
16 
5.3.1 PAZUFLOXACIN 
16 
5.3.1.1 Pharmacodynamics 
16 
5.3.1.2 Eyeball pharmacokinetics 
16 
5.3.1.3 Preclinical studies 
16 
5.3.1.4 Clinical safety studies 
19 
5.3.1.5 Clinical efficacy studies 
19 
5.3.1.6. Safety and tolerability 
20 
5.4 JUSTIFICATION 
20 
5.5 OBJECTIVES AND HYPOTHESIS 
20 
5.5.1 GENERAL PURPOSE 
20 
5.5.2 SPECIFIC OBJECTIVES 
21 
5.5.3 SECONDARY OBJECTIVES 
21 
5.5.4 HYPOTHESIS 
21 
5.6 DESIGN AND STUDY PLAN 
21 
5.6.1 DISCUSSION OF THE STUDY DESIGN 
22 
6. MATERIAL AND METHODS. PARTICIPANTS, INTERVENTIONS AND VARIABLES 
22 
6.1 STUDY CENTER 
22 
6.1.1 ORGANIZATION OF THE CENTER 
23 
6.1.2 DOCUMENTATION TO BE DELIVERED TO THE SPONSOR 
23 
6.1.3 CLOSURE OF THE CENTER 
24 
6.2 ELIGIBILITY CRITERIA 
24 
6.2.1 INCLUSION CRITERIA 
24 
6.2.2 EXCLUSION CRITERIA 
24 
6.2.2.1 General criteria 
24 
6.2.2.2 Medical and therapeutic criteria 
24 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 6 of 59 
 
6.2.3 ELIMINATION CRITERIA 
24 
6.2.4 IDENTIFICATION OF THE SUBJECT 
25 
6.3 INTERVENTION 
25 
6.3.1 ADMINISTERED TREATMENTS 
25 
6.3.1.1 Treatment in study 
25 
6.3.1.2 Reference treatment 
26 
6.3.2 STRATEGIES TO IMPROVE ADHERENCE AND PROCEDURE TO MONITOR ADHERENCE 
26 
6.3.3 TREATMENTS AND CONVENTIONAL INTERVENTIONS PERMITTED AND PROHIBITED BEFORE 
AND DURING THE STUDY 
27 
6.3.4 MANAGEMENT OF TREATMENT 
28 
6.3.4.1 Delivery and reception 
28 
6.3.4.2 Storage 
28 
6.3.4.3 Return 
29 
6.4 UNLOCK VARIABLES 
29 
6.4.1 SECURITY VARIABLES 
29 
6.4.2 EFFICACY VARIABLES 
29 
6.4.2.1 Primary outcome variables 
¡Error! Marcador no definido. 
6.4.2.2 Secondary outcome variables 
29 
6.4.3 METHODS AND SCALES TO BE USED FOR THE MEASUREMENT OF VARIABLES 
¡ERROR! 
MARCADOR NO DEFINIDO. 
6.4.3.1 Biomicroscopy 
30 
6.4.3.2 Global qualification of the researcher 
30 
6.4.3.3 Evaluation of adverse events 
30 
6.4.3.4 Sampling of conjunctival secretion for bacterial culture 
31 
6.4.4 TIME OF VARIABLE MEASUREMENT 
32 
6.5 CHRONOGRAM AND STUDY DIAGRAM 
33 
6.5.1 CHRONOGRAM 
33 
6.5.2 PROCEDURES TO BE PERFORMED BY VISIT 
34 
6.5.2.1 Basal Visit 
34 
6.5.2.2 Visit 1 
35 
6.5.2.4 Final Visit 
35 
6.5.2.5 Security call: 
35 
6.5.3 STUDY DIAGRAM 
36 
6.6 SAMPLE SIZE 
36 
6.6.1 CALCULATION OF SAMPLE SIZE 
36 
6.7  RECRUITMENT 
37 
7. METHODS ASSIGNMENT OF THE INTERVENTION 
37 
7.1 GENERATION OF THE ASSIGNMENT SEQUENCE 
37 
7.2 BLINDING MECHANISM 
37 
7.3 IMPLEMENTATION 
37 
7.4 BLINDING AND MASKING 
37 
7.4.1 BLIND OPENING 
37 
8. METHODS DATA COLLECTION, ADMINISTRATION AND ANALYSIS 
38 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 7 of 59 
 
8.1 METHODS OF DATA COLLECTION 
38 
8.1.1 STRATEGIES TO COMPLETE FOLLOW-UP 
38 
8.2 ADMINISTRATION OF DATA 
38 
8.3 STATISTICAL METHODOLOGY 
39 
8.3.1 ANALYSIS OF PRIMARY AND SECONDARY DISSOLVEMENT VARIABLES 
39 
8.3.2 ADDITIONAL ANALYSIS 
40 
8.3.3 ANALYSIS OF POPULATION AND HANDLING OF MISSING DATA 
40 
9. METHODS MONITORING 
40 
9.1 DATA MONITORING 
40 
9.2 PRELIMINARY ANALYSIS AND EARLY TERMINATION OF THE STUDY 
42 
9.3 ADVERSE EVENTS 
42 
9.3.1 RESPONSIBILITIES OF THE INVESTIGATOR 
42 
9.3.1.1 Record of adverse events in the Case Report Form 
42 
9.3.1.2 Follow up of adverse events 
44 
9.3.1.3 Procedures for a serious adverse event 
44 
9.3.1.4 Causality evaluation 
45 
9.3.2 SPONSOR'S RESPONSIBILITIES 
47 
9.4 AUDIT 
47 
9.4.1 PRE-STUDIO AUDIT 
47 
9.4.2 AUDIT / INSPECTION DURING STUDY DRIVING 
47 
10. ETHICAL CONSIDERATIONS 
47 
10.1 APPROVAL OF THE COMMITTEES 
47 
10.2 AMENDMENTS TO THE PROTOCOL 
48 
10.3 CONSENT 
49 
10.3.1 OBTAINING 
49 
10.3.2 SPECIAL CONSIDERATIONS 
49 
10.3.2.1 Informed consent of parents 
49 
10.3.2.2 Informed consent 
50 
10.3.3 MODIFICATION TO INFORMED CONSENT 
50 
10.4 CONFIDENTIALITY 
50 
10.5 DEVIATIONS 
51 
10.5.1 MANAGEMENT OF DEVIATIONS 
51 
10.6 DECLARATION OF INTEREST 
52 
10.7 ACCESS TO INFORMATION 
52 
10.8 AUXILIARY CARE AND SUBSEQUENT TO THE COMPLETION OF THE STUDY 
52 
10.9 BIOSECURITY ASPECTS 
52 
10.10  FINAL REPORT AND PUBLICATION OF RESULTS 
52 
10.10.1 FINAL REPORT 
52 
10.10.2 COMMUNICATION OF RESULTS 
52 
10.10.3 PUBLICATION OF RESULTS 
53 
11. REFERENCES 
55 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 8 of 59 
 
12. SIGNATURE PAGE 
59 
12.1 SIGNATURES OF THE SPONSOR'S REPRESENTATIVES 
59 
12.2 INVESTIGATOR 
59 
 
Index of tables, figures and illustrations 
Table 1. Administrative structure ....................................................... ¡Error! Marcador no definido. 
Table 2. Antibiotic treatment of acute bacterial conjunctivitis ......... ¡Error! Marcador no definido. 
Table 3. Quali-quantitative formulation of PRO-157 ......................... ¡Error! Marcador no definido. 
Table 4. Rest period of medications with ophthalmic application .... ¡Error! Marcador no definido. 
Table 5 Method of measuring variables ............................................. ¡Error! Marcador no definido. 
Table 6. Algorithm of Karch and Lasagna modified by Naranjo ........ ¡Error! Marcador no definido. 
 
 Figure 1. Pharmacokinetic profile, in aqueous humor, of PRO-157, Vigamoxi and Zymar. .......... 18 
 Figure 2. Pharmacokinetic, cornea profile of PRO-157, Vigamoxi and Zymar. ............................. 18 
 Figure 3. Pharmacokinetic profile, in conjunctiva, of PRO-157, Vigamoxi and Zymar. ................. 19 
Figure 4. Study design ......................................................................... ¡Error! Marcador no definido. 
Figure 5. Minimum organization of the center .................................. ¡Error! Marcador no definido. 
Figure 6. Diagram of the study ............................................................ ¡Error! Marcador no definido. 
Figure 7. Adverse event attention ...................................................... ¡Error! Marcador no definido. 
 
Illustration 1. Efron scale for conjunctival hyperemia ....................... ¡Error! Marcador no definido. 
Illustration 2. Conjunctival secretion sampling .................................. ¡Error! Marcador no definido. 
 
 
 
 
 
 
 
 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 9 of 59 
 
3. Index of abbreviations. 
 
AV 
 Visual acuity 
BPC 
 Good clinical practices 
IEC 
 Research Ethics Committee 
CI 
 Informed Consent 
CRF  
Case Report Form (Case Report Form) 
CV  
Visual capacity 
EA / EAS  
Adverse event / serious adverse event 
FDA  
Food and Drug Administration (Food and Drug Administration) 
ICH  
International Conference on Harmonization (for its acronym in English 
International Conference on Harmonization) 
IP 
 Principal investigator of the clinical study 
PIO 
 intraocular pressure 
VDF 
 Verification of source documents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 10 of 59 
 
 
 
 Page left intentionally blank


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 11 of 59 
 
4. Administrative structure of the study. 
The administrative structure of the sponsoring party, corresponding to Sophia Laboratories, S.A. of 
C.V. is shown in Table 1. Administrative structure. 
Function 
Contact/ name 
Membership ¥ 
Medical 
responsible 
for the study 
Dr. Leopoldo Martín Baiza Durán 
leopoldo.baiza@sophia.com.mx 
Medical Director and Regulatory 
Affairs 
Director of 
the study 
QFB. Francisco García Velez 
francisco.garcia@sophia.com.mx 
Clinical Operations Manager 
Scientific 
Comittee 
Dr. Oscar Olvera Montaño 
oscar.olvera@sophia.com.mx 
Ophthalmologist Investigator 
Scientific 
Comittee 
Dr. en C. Patricia del Carmen Muñoz Villegas 
paticia.muñoz@sophia.com.mx 
Biostatist 
Scientific 
Comittee 
Dr. en C. Ricardo Alonso Llamas 
ricardo.llamas@sophia.com.mx    
Clinical Pharmacologist 
¥ Employees of Sophia Laboratories, S.A. of C.V Av. Paseo del Norte No.5255, Col. Guadalajara Technology Park, 
Carretera Guadalajara-Nogales Km13.5 C.P. 45010 Zapopan, Jalisco, Mexico Tel +52 (33) 3000 4200 
Table 1. Administrative structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 12 of 59 
 
 
 
 Page left intentionally blank


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 13 of 59 
 
5. Introduction 
5.1 Theoretical framework 
Conjunctivitis, or inflammation of the conjunctiva, is a general term that refers to a group of diseases 
/ disorders that mainly and primarily affect the conjunctiva, differentiating from those diseases in 
which the inflammation of the conjunctiva is secondary to other diseases. [1] 
Conjunctivitis is a very common disease, which can affect any age group, presenting a classic 
semiology, more non-specific, such as conjunctival hyperemia, secretion, lachrymation, foreign 
body sensation, pain and pruritus among others. [1] It is estimated that acute conjunctivitis affects 
6 million people annually in the United States of America. [2] 
Due to its etiology, conjunctivitis is classified as infectious or non-infectious. Among the non-
infectious are the allergic, the irritative (mechanical or toxic), the mediated by immunity and the 
neoplastic. The causes of infectious diseases include viruses and bacteria. [1] 
The bacterial conjunctivitis is divided in turn, according to the course and severity, in hyperacute, 
acute and chronic. Hyperacute bacterial conjunctivitis is characterized by an abrupt onset, with 
purulent yellow-green discharge, profuse and thick, mixed ocular injection and chemosis, 
sometimes accompanied by the formation of an inflammatory membrane. [3] [4] Its most frequent 
etiological agent is Neisseria gonorrhoeae, and can cause corneal lesions, perforations and even 
endophthalmitis if not treated in a timely manner. [5] 
In chronic bacterial conjunctivitis, the clinical picture lasts at least 4 weeks, with frequent relapses. 
Conjunctival hyperemia and secretion are mild. Coagulase positive and negative staphylococci are 
the most common organisms involved. [3] 
Globally, the most common presentation of bacterial conjunctivitis is acute. Some variations in the 
presentation of cases of acute bacterial conjunctivitis have been described, showing a peak in the 
period from December to April in the northern hemisphere, corresponding to winter, while viral 
conjunctivitis has its peak in the summer months and conjunctivitis. allergic during the spring. [6] 
[7] [8] It is estimated that in developed countries, 1-4% of general medical consultations have the 
red eye as a reason for consultation, and that most of these are diagnosed as acute bacterial 
conjunctivitis. [9] [10] [11] [12] [13] In countries such as Norway, it has been suggested that in 30 
out of every 1000 patients who attend a general medical consultation, there is a diagnostic 
impression of acute bacterial conjunctivitis, this being confirmed diagnosis in 2 of 3 cases. [5] 
Epidemiological data on bacterial conjunctivitis tend to differ among authors, due in large part to 
the fact that most cases of conjunctivitis are treated at the first level of medical care, and it has been 
suggested that general practitioners diagnose conjunctivitis bacterial. [5] 
 
5.1.1 Etiology of bacterial conjunctivitis. 
 
In healthy subjects, it is common for microorganisms to be isolated from their conjunctiva. The 
conjunctiva under normal circumstances presents a flora with bacterial colonization and transient 
or recurrent bacterial contamination. Colonization means the stable presence of microorganisms, 
in balance with host defense mechanisms; while the contamination represents microorganisms 
introduced from sources external to the conjunctiva. [14] Most of the microorganisms present, in a 
healthy conjunctiva, are due to transient or recurrent contamination, true colonization is more 
common in the palpebral margins. Given the right conditions, any microorganism can cause an 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 14 of 59 
 
infection. A primary pathogen consistently produces infections, opportunists require that the 
individual's immunity be compromised, while most microorganisms act as incidental pathogens, 
that is, they replicate and cause disease when the host's defense mechanisms are affected they see 
compromised. [15]  
In samples of healthy conjunctiva, it is common to isolate coagulase-negative staphylococci and 
corynebacteria, and it has been reported that in normal, non-inflamed conjunctiva, coagulase-
positive staphylococci, streptococci, haemophilus, moraxella, and gram-negative bacilli have also 
been isolated, which are organisms traditionally pathogenic [16] [17] [4] 
The most frequent causative agents of bacterial conjunctivitis are: S. aureus, S. epidermidis, H. 
influenzae, S. pneumoniae, S. viridians, Moraxella catarrhalis and gram-negative intestinal bacteria. 
[4] Varying in its presentation, according to climatic, social, hygienic and age conditions. 
However, several studies have shown a high frequency of negative bacteriological cultures in 
patients with classical symptoms of acute bacterial conjunctivitis, reporting up to 22-68% of 
negative cultures. [18] [19] [20] [21] The variation in this frequency, has been tried to explain by the 
different interpretations that the authors give the results of the cultures. 
5.1.2 Clinical picture of acute bacterial conjunctivitis 
The symptoms of acute bacterial conjunctivitis can present a wide spectrum of signs and symptoms, 
and the severity of these. However, classically, the onset of bacterial conjunctivitis with a unilateral 
foreign body sensation, secretion and conjunctival hyperemia is described. Symptoms can become 
bilateral in one or two days. The secretion evolves to be more copious and purulent, the "sticky 
eyes" in the morning are a very common symptom. In some patients the condition is accompanied 
by pain or burning. Although these symptoms are generally accepted as typical of acute bacterial 
conjunctivitis, they have not been classified as diagnostic criteria based on evidence for the 
differentiation between bacterial and viral conjunctivitis. [22] 
Conjunctival hyperemia is the rule, being more intense in the peripheral bulbar conjunctiva and less 
intense towards the limbus. In more severe cases, conjunctival hyperemia can be totally generalized. 
The secretion can occur throughout the palpebral fissure, or only in the cul-de-sac or as yellowish 
incrustations on the eyelid margin. [5] 
In patients diagnosed with bacterial conjunctivitis, conjunctival hyperemia has been reported in all 
cases, secretion in 85-90% of cases, foreign body sensation in 90%, and 50% with various degrees of 
burning or pruritus.[23] 
5.1.3 Treatment of acute bacterial conjunctivitis. 
 
Acute bacterial conjunctivitis is a disease with a good prognosis and self-limiting in at least 60% of 
cases in non-immunocompromised adults. [11] The use of antibacterial therapy is associated with 
an earlier clinical and bacterial remission, compared with placebo on days 2 and 5 of treatment. 
These advantages over placebo remain on days 6 and 10, but tend to decrease with time extension. 
[1] 
The choice of antibiotic is usually made empirically. Because a course of 5-7 days with broad 
spectrum antibiotic is sufficiently effective, you can choose the option that is most convenient; there 
is still no clinical evidence to suggest the superiority of any particular antibiotic. [1] [24] 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 15 of 59 
 
Classically, chloramphenicol has been the most widely used antibiotic for the treatment of bacterial 
conjunctivitis, nevertheless, due to its adverse effects other safer alternatives have been preferred. 
Being drugs such as tobramycin and fluoroquinolones the most chosen as first-line drugs. The table 
shows the evidence of the use of topical antibiotics for the treatment of acute bacterial 
conjunctivitis. Sometimes an anti-inflammatory can be added to decrease symptoms more quickly. 
[1] [24] 
Table 2. Antibiotic treatment of acute bacterial conjunctivitis. 
Diagnosis 
Epidemiology 
Type of 
secretion 
Cause 
Treatment 
Level of 
evidence 
Acute 
bacterial 
conjunctivitis 
135 cases per 
10,000 hab. 
Purulent 
S. aureus 
S. epidermidis 
H. influenza 
S. pneumoniae 
S. viridans 
Moraxella 
Aminoglycosides 
 
    Gentamicin 
B 
    Tobramycin 
A 
Fluoroquinolones 
 
    Besifloxacin 
A 
    Ciprofloxacin 
A 
    Gatifloxacin 
B 
    Levofloxacin 
B 
    Moxifloxacin 
A 
    Ofloxacin 
A 
Macrolides 
 
    Azithromycin 
A 
    Erythromycin 
B 
Sulfonamides 
 
    Sulfacetamide 
B 
Modified from Azari AA. [25] 
All the guidelines recommend a responsible and non-indiscriminate use of antibiotics and anti-
inflammatories. 
5.2 Definition of the problem and fundamental reason 
It is estimated that in the treatment of bacterial conjunctivitis an expense of $ 377 to $ 857 million 
dollars is made. [25] Without counting the socio-economic burden that the acute stage of the 
disease produces on the individual, reflecting with work or school absenteeism and a decrease in 
productivity. 
Although it is accepted that acute bacterial conjunctivitis has a self-limiting course and a favorable 
prognosis, antibiotic treatment provides an earlier clinical remission of the disease and theoretically 
prevents the appearance of more serious complications such as keratitis. 
Currently, there is a wide variety of antibiotics in ophthalmic solution, from different families, such 
as macrolides, aminoglycosides, sulfas and fluoroquinolones. Many of these medications are also 
used in more serious infections, so development of bacterial resistance is highly undesirable. [5] 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 16 of 59 
 
The pazufloxacin, active ingredient of PRO-157, is a fourth-generation fluoroquinolone that has not 
been marketed for ophthalmic use. Currently, up to 26% resistance to the 4th generation quinolones 
(moxifloxacin, gatifloxacin, and levofloxacin) is reported in strains of methicillin-resistant S. 
epidermidis [26], so pazufloxacin represents a treatment option. 
5.3 Background 
 
Among the therapeutic options for bacterial conjunctivitis, there are quinolones. [27] The mesolate 
of pazufloxacin, is a member of this family, nevertheless, it differs in chemical structure since it was 
added an amino group in carbon 10, which increases its pharmacological potency and allows it to 
expand its antimicrobial spectrum. [28] 
The pazufloxacin, is currently marketed in Japan in injectable form, for the treatment of respiratory 
infections with a broad spectrum and a powerful activity. [29] Sophia Laboratories, S.A of C.V has 
created a drug in ophthalmic presentation that contains pazufloxacin as an active ingredient, and its 
clinical development program has shown favorable results in phase I and phase II studies. 
5.3.1 Pazufloxacin  
The fourth generation fluoroquinolone pazufloxacin is a fused tricyclic quinolone, with a 1-
aminocyclopropyl substitute at the C10 position, unique property of the molecule that contributes 
to the broad spectrum and potent activity of this drug. [30] Originally developed for systemic use in 
the treatment of respiratory tract infections. [29]  
5.3.1.1 Pharmacodynamics  
 
Pazufloxacin has demonstrated a multimodal mechanism of action and inhibits both the DNA gyrase 
enzyme and the topoisomerase IV enzyme, increasing the antibacterial spectrum. In addition, 
pazufloxacin has also shown antagonistic DNA actions; The mechanism of multimodal action is 
linked to the potential for the development of resistance in pazufloxacin and it has been confirmed 
that it is not affected by said mechanism. [28] 
5.3.1.2 Eyeball pharmacokinetics. 
 
Route of administration: Ophthalmic. 
Release: immediate. 
Absorption: At the ocular level it is easy to penetrate the cornea and concentrations of said 
quinolone have been detected in aqueous humor. One of the characteristics of this molecule is its 
ability to penetrate intracellularly, which favors its bactericidal action. [31] 
Metabolism: The quinolones may undergo different metabolic reactions such as glucuronidation, 
hydroxylation and oxidation depending on the participating drug. In general terms, the metabolites 
have less antibacterial activity than the compounds of origin. [31] 
Elimination: It is mostly eliminated by the kidney, by the mechanism of tubular secretion, some of 
the metabolites may undergo entero-hepatic circulation. [31][17] 
5.3.1.3 Preclinical studies 
Sophia Laboratories has carried out studies in animal models to evaluate the safety and 
bioavailability of pazufloxacin. Other studies have been reported in systemic application, 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 17 of 59 
 
nevertheless we will only show those of ophthalmic route, for more information you can refer to 
the manual of the researcher of PRO-157. 
In a study conducted in New Zealand albino rabbits, the safety and toxicity of PRO-157 after its 
ophthalmic application was evaluated, compared to the ophthalmic solutions of moxifloxacin 0.6% 
(Vigamoxi®, Alcon Laboratories) and gatifloxacin 0.3% (Zymar®, Allergan Inc.) The intervention 
consisted in the application of 1 drop in the bottom of the sac of both eyes, of the products under 
investigation, 4 times a day, for 30 days. Thirty rabbits were included in the study, 10 per group. 
Visits were made on days 2, 7, 10, 15, 20, 25 and 30; on day 31 the animals were sacrificed and the 
eyes were enucleated for the histopathological analysis of the cornea, conjunctiva and retina. The 
safety variables to be evaluated were conjunctival hyperemia, secretion, intraocular pressure, 
corneal staining (lysine and fluorescein green) and the presence of adverse events (AD). Only 
alterations in the stains were reported from day 10 in the groups of PRO-157 and moxifloxacin, 
nevertheless there were no statistically significant differences; no changes were found in the PIO. 
The toxicity was evaluated by histopathological analysis of cornea, conjunctiva and retina, which 
showed no alterations in any of the groups. The authors of the study concluded that the use of PRO-
157 is equally safe and non-toxic, following their ophthalmic in albino rabbits New Zealand, than the 
use of the ophthalmic solutions of moxifloxacin 0.6% and gatifloxacin 0.3%. [32] 
Sophia Laboratories, S.A. of C.V. also conducted a distribution study in the eye of albino New Zealand 
rabbits, with the PRO-157. Ninety-six rabbits were included in the study, which were divided into 
three groups corresponding to the investigational drugs: PRO-157 (n = 32), Vigamoxi® (n = 32) and 
Zymar® (n = 32). Each group was divided into 8 subgroups, which corresponded to the sampling time 
points (15min, 1h, 3h, 4h, 6h, 8h, 12h, and 24h). After the application of a dose of 30μl, of the 
corresponding investigational product, in bottom of bag, in both eyes, the rabbits were sacrificed at 
the determined point of time and samples of aqueous humor, conjunctiva and cornea were taken. 
These were later analyzed by high performance liquid chromatography. The results are shown in 
the figures: Figure 1, Figure 2 and Figure 3. [33] 
An adequate penetration of PRO-157 was observed in conjunctiva, cornea and aqueous humor, after 
the application of a dose on the ocular surface. The Tmax was 15 minutes for cornea and 
conjunctiva, and 1 hour for aqueous humor. Showing behavior similar to that of the other 
fluoroquinolones evaluated. 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 18 of 59 
 
Figure 1. Pharmacokinetic profile, in aqueous humor, of PRO-157, Vigamoxi and Zymar. 
 
 
Figure 2. Pharmacokinetic profile, in cornea, of PRO-157, Vigamoxi and Zymar. 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 19 of 59 
 
Figure 3. Pharmacokinetic profile, in conjunctiva, of PRO-157, Vigamoxi and Zymar. 
 
 
 
5.3.1.4 Clinical safety studies. 
Studies have been reported in systemic application, nevertheless we will only show those of 
ophthalmic route, for more information of clinical safety studies by other administration routes it 
can refer to the manual of the researcher of PRO-157. 
In a phase I study, carried out in 30 healthy subjects, PRO-157 was applied 4 times a day (every 6 
hours), for 10 days. There were 3 follow-up visits on days 2, 4 and 7, and a final visit on day 11. The 
primary safety variables were: visual acuity, ocular surface staining with fluorescein and lysamine 
green, PIO and presence of EA. The tolerability variables were burning, hyperemia, chemosis, foreign 
body sensation, lacrimation, pruritus and secretion. In the safety variables there were no changes 
between the baseline and the final visit, there were no adverse events. Regarding tolerability, 
burning was the most common symptom in all visits, reporting as mild in 48-70% of cases, the 
highest incidence of burning reported as severe was on day 2, with 27% of cases. [34]  
5.3.1.5 Clinical efficacy studies. 
Studies have been reported in systemic application, nevertheless we will only show those of 
ophthalmic route, for more information on efficacy clinical studies by other routes of 
administration, refer to the manual of the researcher of PRO-157. 
In a phase II, multicentric, double masked, randomized and active control study, the efficacy, in the 
treatment of bacterial conjunctivitis, of the PRO-157 formulation (pazufloxacin 0.6%) was tested in 
3 different posologies (twice per day, three times a day and 4 times a day), compared to the 
ophthalmic solutions of moxifloxacin 0.6% (Vigamoxi®, Alcon Laboratories) and gatifloxacin 0.3% 
(Zymar, Allergan Inc.) 3 times a day. A total of 300 eyes with a clinical diagnosis of bacterial 
conjunctivitis were included in the study. The intervention lasted 7 days. The efficacy variables were 
the clinical remission of the disease and bacterial eradication on day 7. The instillation of 1 drop 3 
times a day of PRO-157 for 7 days, is the dose that showed greater efficacy in relation to the 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 20 of 59 
 
comparators. Nevertheless, this difference did not have statistical significance among the groups 
based on bacterial eradication. From the clinical perspective, the main difference was observed in 
the decrease of conjunctival hyperemia and chemosis, which was absent at the end of the 
intervention in the group with the indicated posology. In the overall clinical efficacy a statistical 
difference was observed between the group that was applied 1 drop 3 times a day vs 1 drop 2 times 
a day. Regarding tolerability, the main symptoms were burning, foreign body sensation and pruritus; 
which are difficult to distinguish if they are due to the physico-chemical characteristics of the 
molecule or inherent to the chosen disease model. Nevertheless, no differences were observed in 
these parameters between the groups. [35] 
5.3.1.6. Safety and tolerability. 
Ophthalmic fluoroquinolones have a similar safety and tolerability profile, being generally well 
tolerated. Burning and discomfort post-stuttering is the most reported discomfort. With the use of 
PRO-157, the presence of white crystalline deposits, related to the use of other topical 
fluoroquinolones such as ciprofloxacin, has not been reported. 
In the clinical studies carried out with PRO-157, conjunctival hyperemia and foreign body sensation 
have been reported after burning. Symptoms that have been reported as transient. 
5.4 Justification 
PRO-157 is a 0.6% pazufloxacin formulation in ophthalmic solution, developed by Sophia 
Laboratories, S.A. of C.V. which has demonstrated an acceptable safety profile in preclinical and 
clinical phase I studies, a bioavailability, in animal models, similar to that of other fourth generation 
fluoroquinolones and efficacy in the treatment of bacterial conjunctivitis in a phase II clinical study. 
With this background, a phase III clinical study is required to verify the efficacy profile of PRO-157. 
Complying with the clinical development plan of a new fourth generation fluoroquinolone will allow 
Sophia Laboratories, S.A. of C.V. make available to physicians a safe and effective alternative for the 
treatment of ocular surface infections. In the context of increasing bacterial resistance, to the 
antibiotics currently available, this new option may prove valuable. Notwithstanding, because the 
present study aims to demonstrate the efficacy in the treatment of bacterial conjunctivitis, it would 
provide a foundation for future studies where the indication for more serious pathologies, such as 
keratitis and intraocular infections, can be extended; this based on the bioavailability behavior 
demonstrated in preclinical studies. 
The outcome variable of primary outcome is the clinical remission of the disease. Understanding 
that in the clinical context of the treatment of this disease, empirical treatment with a broad-
spectrum antibiotic is common, due to the nature of the disease (how quickly it can be resolved in 
a natural course); reserving the use of cultures for neonatal conjunctivitis, recurrent, resistant to 
initial treatment and in suspicion of gonococcal infection (bacterial conjunctivitis hyperacute) or 
chlamydia. [1] Given this context, resembling clinical practice, is that the present study is proposed. 
Notwithstanding, the crop is considered as a scientific support for diagnosis and bacterial 
eradication as a secondary outcome point. 
5.5 Objectives and hypothesis. 
5.5.1 General purpose. 
To compare the efficacy of the ophthalmic solution of pazufloxacin 0.6%, against the ophthalmic 
solution of gatifloxacin 0.3%, in the treatment of acute bacterial conjunctivitis. 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 21 of 59 
 
5.5.2 Specific objectives. 
 
- 
To evaluate the efficacy of PRO-157 by the clinical remission of acute bacterial conjunctivitis 
on day 8, through the absence of conjunctival secretion and bulbar hyperemia. 
- 
To evaluate the efficacy of PRO-157 by decreasing the degree of hyperemia and conjunctival 
secretion during visits. 
- 
To evaluate the efficacy of the ophthalmic solution of gatifloxacin 0.3%, by means of the 
clinical remission of acute bacterial conjunctivitis on day 8, by means of the absence of 
conjunctival secretion and bulbar hyperemia. 
- 
To evaluate the efficacy of the ophthalmic solution of gatifloxacin 0.3%, by decreasing the 
degree of hyperemia and conjunctival secretion during visits. 
5.5.3 Secondary objectives. 
- 
To evaluate the efficacy of PRO-157 by bacterial eradication with respect to baseline, on day 
8. 
- 
To assess the efficacy of PRO-157 by decreasing the researcher's overall rating of clinical 
changes and symptoms during visits. 
- 
Evaluate the safety of PRO-157 through the presence of EA. 
- 
To evaluate the efficacy of the ophthalmic solution of gatifloxacin 0.3%, by bacterial 
eradication with respect to the baseline on day 8. 
- 
To evaluate the efficacy of the 0.3% gatifloxacin ophthalmic solution, by decreasing the 
researcher's overall rating of clinical changes and symptoms during visits. 
- 
To evaluate the safety of the ophthalmic solution of gatifloxacin 0.3%, through the presence 
of EA. 
5.5.4 Hypothesis. 
H0I: The ophthalmic solution PRO-157 is not inferior in the treatment of bacterial conjunctivitis, 
compared to the ophthalmic solution of gatifloxacin 0.3%, by means of the clinical remission of the 
disease. 
Ha: The ophthalmic solution PRO-157 is inferior in the treatment of bacterial conjunctivitis, 
compared to the ophthalmic solution of gatifloxacin 0.3%, by means of the clinical remission of the 
disease. 
5.6 Design and plan of the study. 
Phase III clinical study of noninferiority, multicenter, double blind, with comparative group, of 
parallel groups, with randomization. Patients with clinical diagnosis of acute bacterial conjunctivitis 
will participate, who will be randomly assigned to 2 intervention groups. One group will receive the 
study formulation PRO-157 and the other group will be exposed to gatifloxacin 0.3%. 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 22 of 59 
 
 
Figure 4. Study design. 
5.6.1 Discussion of the study design. 
In clinical research it is common to propose trials with the objective of evaluating the efficacy of a 
product under investigation against a reference medicine or active control, in order to compare the 
new product under investigation from a clinical or statistical point of view to a drug commercially 
available 
The clinical trial is the ideal model to evaluate the effectiveness of two interventions, it allows 
obtaining the highest quality evidence among different types of research. The characteristics of 
randomization and double blind, allow to avoid biases (selection, evaluation, etc.) that can not be 
avoided with other models. Being controlled and parallel groups allows distinguishing the effects of 
interventions in isolation. 
The proposed clinical trial aims to evaluate the efficacy and safety profile of a 0.6% pazufloxacin 
formulation and compare it against the efficacy and safety profile of the administration of a 
commercially available fluoroquinolone widely used for its known efficacy and safety profile.  
 
6. Material and methods. Participants, interventions and variables. 
6.1 Study Center. 
The present study will be performed in ophthalmology offices duly equipped and registered for their 
proper functioning. According to the needs of the sponsor, these may be private or public, be 
attached to a hospital or clinic or be independent. 
This is a multicentric study that is intended to be carried out in the Mexican Republic. It is foreseen, 
primarily to open centers in the cities of Guadalajara, Monterrey and Mexico City; not excluding, 
that according to the needs of the sponsor, other centers may be required within the Republic. 
 
Random assignment (eyes with clinical 
diagnosis of acute bacterial conjunctivitis) n 
= 160
PRO-157 (n=80)
Efficacy (clinical remission day 8)
Security (presence of EA)
Gatifloxacin 0.3% (n=80)
Efficacy (clinical remission day 8)
Security (presence of EA)


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 23 of 59 
 
6.1.1 Organization of the center. 
Each study center will have a principal investigator (IP). The IP is the ophthalmology specialist in the 
clinical study. 
The IP is responsible for forming a multidisciplinary research team to carry out the clinical study 
according to protocol, under its scientific guidance. It is the prerogative of the IP the design of the 
organization of its center and the selection of the personnel that will perform the functions. 
Notwithstanding, the minimum organization of the research team requested by the sponsor 
requires the figure of sub-researcher, study coordinator and pharmacist. 
 
 
 
 
 
 
 
Figure 5. Minimum organization of the center 
Any person to whom the IP designates, under his / her responsibility, a part of the follow-up of the 
study (co-investigator, sub-researcher, nurse, etc.) or a specific function of participation in the study 
(pharmacist, administrative assistant, study coordinator, etc.) It must appear in the "Delegation of 
Responsibilities" format. 
The "Delegation of Responsibilities" and the "Organizational Chart of the Center" must be delivered 
to the sponsor before the start of the study and updated if the members or their responsibilities are 
changed. 
6.1.2 Documentation to be delivered to the sponsor. 
The IP must deliver to the sponsor, before the start of the study: 
- Curriculum vitae updated, in Spanish, dated and signed (maximum 10 pages), of the IP and the 
staff that integrates its organizational chart of the center. 
- Copy of IP academic certifications (degree certificate and specialty diploma in ophthalmology, 
federal professional certificates). 
- Copy of academic certifications of the maximum degree obtained, from each one of the members 
of your research team, that cover their capacity to perform the delegated functions. 
- Copy of operating notice or similar issued by corresponding regulatory entity (When applicable) 
- Certificate of good clinical practice in force. If the issuing institution does not specify the validity 
period in the certificate, the date of issue of the certificate must not exceed one year 
- Letter of declaration of interests of the IP and subinvestigador. 
 
Principal 
investigator
Subinvestigator
Pharmacist
Study 
coordinator


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 24 of 59 
 
6.1.3 Closure of the center. 
The closing of the center will be carried out once the last visit of the last included subject previously 
agreed between the sponsor and the IP has been made. The closing process will be according to the 
internal operating procedures of the sponsor. 
It is the sponsor's prerogative to prematurely close a study center, it must inform the IP the reasons 
for the closure. 
6.2 Eligibility criteria. 
6.2.1 Inclusion criteria. 
-Signed informed consent. 
-Age ≥ 1 year. 
-Both genders. 
-Clinical picture of acute bacterial conjunctivitis defined by: 
º Conjunctival secretion 
º Conjunctival bulbar hiperemia 
6.2.2 Exclusion criteria. 
6.2.2.1 General criteria. 
I. 
Pregnant women, lactating or planning to become pregnant. 
II. 
Women of reproductive age and who do not have a hormonal contraceptive method, 
intrauterine device or bilateral tubal obstruction. 
III. 
Participation in another clinical research study ≤ 30 days before the baseline visit. 
IV. 
Previous participation in this same study. 
V. 
That they can not comply with their attendance at appointments or with all the 
requirements of the protocol. 
6.2.2.2 Medical and therapeutic criteria. 
I. 
Single eye 
II. 
Presence of corneal abrasion or corneal ulceration in the study eye. 
III. 
History Users of contact lenses who are not willing to suspend their use during the study. 
IV. 
Users of any formulation with ophthalmic application, including lubricants, that can not, or 
do not want to suspend it during the study. 
V. 
Antecedents of eye surgery 6 weeks prior to study entry. 
VI. 
Viral or allergic conjunctivitis. 
VII. 
Active uveitis. 
VIII. 
Active ulcerative keratitis. 
IX. 
Recurrent corneal erosion syndrome 
X. 
Antecedent of hypersensitivity or allergy to fluoroquinolones. 
6.2.3 Elimination criteria. 
I. Subject's decision. The subject may decide unilaterally to withdraw from the study at any time. 
II. Pregnancy. 
III. Presence of a serious adverse event (EAS), including the presence of hypersensitivity. 
IV. Investigator's decision: 
a. Due to the presence of an EA that, although not serious, at the discretion of the 
IP merits the prescription of a medicine not authorized in the protocol. 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 25 of 59 
 
V. Any deviation to the protocol that affects the security of the subject. 
6.2.4 Identification of the subject. 
 The patients of the study will be identified by a number and the initials of their name. 
The initials of the study subject will be obtained by starting with the first letter of the name, followed 
by the first letter of the first surname and the first of the second, obtaining maximum three letters, 
in case the person has two names or a compound surname will always be used the first letter of the 
first name or last name composed. 
Example: 
1. Adolfo Daniel Mercado Carrizales 
a. a. Initials: AMC 
2. Juan De la Torre Orozco 
a. Initials: JDO 
       3. Luis Carlos Pérez-Gómez Ramírez 
a. Initials LPR 
In the counting stage, the participant number will be assigned consecutively, using 3 consecutive 
digits. Once the subject has been selected, he will be assigned a number with which he will be 
identified throughout the study. Said code will be composed of eight numbers in the following order 
from left to right: 
• Three digits of the molecule under study according to the denomination by the sponsor. 
• Two digits corresponding to the research center number 
• Three digits of the number consecutive to its inclusion assigned in the research center. 
 
Example: 
 
6.3 Intervention. 
6.3.1 Managed treatments. 
The treatments will be administered three times a day, at approximate intervals of 6 hours during 
the waking period, for 7 days. The interventions will be applied in both eyes. Independently that 
only one eye will be provided for the efficacy analysis. 
6.3.1.1 Treatment in study. 
• 
PRO-157  
o Active ingredients: Pazufloxacin 0.6% 
o Pharmaceutical form: ophthalmic solution. 
o Prepared by: Sophia Laboratories, S.A. of C.V. 
o Dosage: 1 drop 3 times a day for 7 days both eyes 
157-01-001 
Key to the molecule 
center number 
number of 
inclusion 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 26 of 59 
 
o Description of the solution: transparent colorless solution. 
o Description of container: sterile multi-dose bottle. 
o The product has certificates of sterility and stability, which are in the master folder 
of the study, and its characteristics are included in the researcher's manual. 
Table 3. Quali-quantitative formulation of PRO-157. 
Active principle 
Quantity 
mg / dL 
% 
Function 
Pazufloxacin 
6 
0.6 
Antibiotic 
Additives 
Quantity 
% 
Function 
Sodium chloride 
Not shown 
Not shown 
Osmotic agent 
Disodium edetate dihydrate 
Not shown 
Not shown 
Chelating agent 
Water for cbp injectable 
preparation (1) 
Not shown 
Not shown 
Vehicle 
Qualitative composition of the formulation PRO-157. The agents that constitute the active substance and the additives are shown. 
Pharmaceutical form: emulsion. (1) How much is enough to. 
6.3.1.2 Reference treatment. 
• 
Zymar®  
o  Active ingredients: Gatifloxacin 0.3% 
o  Pharmaceutical form: Ophthalmic solution 
o  Prepared by: Allergan, S.A. of C.V. 
o  Dosage: 1 drop 3 times a day for 7 days both eyes. 
o  Description of the solution: transparent, crystalline solution. 
o  Description of the container: multi-dose dropper bottle. 
o  The data on characterization and stability of the reference product will be 
supported by its batch number and the manufacturer's insert. 
6.3.2 Strategies to improve adherence and procedure to monitor adherence. 
Strategies: 
• 
• At each visit, the IP reaffirms in the research subject the importance of following the 
indicated regimen and will ask if it has had any inconvenience in following the indications, 
if necessary it will retrain the subject in the application of the medications. 
• 
• In case the IP considers it necessary, the subjects that have an email, the IP or the person 
designated for this, will send them emails to remember the adherence to the treatment and 
the importance of it. The content of the emails will be previously submitted to the research 
ethics committee for approval. 
• 
• By means of the revision of the daily tool of the subject. 
 
 
 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 27 of 59 
 
Procedure to monitor adherence: 
• 
• The evaluation of the adherence by means of the diary of the subject will be carried out 
in the following way: 
𝐴𝑑= (𝐴𝑟)100/𝐴𝑖 
Where: 
Ad = Adherence 
Ar = registered applications. 
Ai = Indicated applications. 
 
Only subjects with a minimum adherence of 80% by means of the subject's daily tool will be 
considered for efficacy analysis. 
6.3.3 Treatments and concomitant interventions allowed and prohibited before and during 
the study. 
The subjects admitted correctly to the study, who meet the eligibility criteria, may continue with 
the systemic treatment of the underlying diseases. If during the development of the study they 
require the implementation of a new permitted medication, they may do so. All concomitant 
medications used must be duly reported in the notes of the clinical file and in the corresponding 
section. 
Allowed medications: 
• Ophthalmic: 
All permitted medications applied via ophthalmic during the study, must wait a minimum period of 
10 minutes from the last application of the treatments under study or reference. The above in order 
to avoid the interaction of treatments in the tear film, based on the tear flow index and the 
physiological tear volume. [36]  
o  Tetracaine 0.5% 
o  Tropicamide 0.8% / Phenylephrine 5% 
• Administered by a route other than ophthalmic: 
 
o Medicines whose effect may be susceptible of modifying any of the parameters of efficacy, 
 
safety or tolerability of this research protocol must notify their clinical monitor or the 
 
scientific committee of the sponsor to judge the convenience of entry, continuation or 
 
elimination of the participant according to correspond 
Any medication allowed that is used, besides appearing in the clinical note, must be registered in 
the section of concomitant medications in the CRF. 
Prohibited drugs: 
- 
- Any medication with ophthalmic application that is not on the list of allowed medications. 
The rest period prior to entering the study is according to the table. 
 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 28 of 59 
 
Table 4. Rest period of medications with ophthalmic application. 
Type of medication 
Example 
Rest period 
Ophthalmic anti-inflammatories (Steroids and NSAIDs) Diclofenac 
Dexamethasone 
48 hours 
Ophthalmic antibiotics 
Ciprofloxacin 
Tobramycin 
24 hours 
Any other ophthalmic medication, including lubricants Hipromellose 
Timolol 
2 hours 
 
6.3.4 Treatment management. 
The treatments will be provided by Sophia Laboratories, S.A. of C.V., for each research center. They 
will be labeled and reconciled. The handling of the treatment will be under the responsibility of the 
IP or a designated member of his team. 
6.3.4.1 Delivery and reception. 
The sponsor will be responsible for delivering the study treatments at the research center according 
to internal procedures. The delivery will be made in closed boxes by means of a courier service or 
directly by the sponsor's staff to the address of the research center according to the study plan. 
The reception will be exclusively carried out by the team of the research center, by the pharmacist. 
You should check the good condition of the primary packaging (box). In the event that it shows 
alterations or defects in its integrity that from its judgment could have damaged the content, it 
should report it to the sponsor. If the package does not show significant defects, it will proceed to 
open it.  
Inside you must locate the acknowledgment document and the logger (data logger) of temperature 
and humidity. You should check that the registered temperature and humidity comply with the 
specifications for transport and shelter (see 6.3.4.2 Storage). Subsequently verify the content 
(treatments) with what is reported in the document. In case the document corresponds to the 
content, it will sign the receipt and send it to the sponsor. Otherwise, notify the sponsor. 
In the study center, the pharmacist will deliver the corresponding treatment to the subjects 
admitted. The center must register the medicine delivered. 
6.3.4.2 Storage . 
The medication must be stored in a secure area with restricted access. Storage should be at room 
temperature to no more than 30 ° Celsius. 
The research center has the obligation to record, in the format designated by the sponsor, the 
temperature and humidity registered in the data logger. This record should include the current 
temperature and humidity, as well as the minimum and maximum of each of these. It must be done 
at least once a day, on business days. 
Said data will be compared by the clinical monitor according to the registration in the data logger.   
    


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 29 of 59 
 
6.3.4.3 Return . 
The research subjects will return, to the personnel indicated by the IP in the center, their treatments 
in the final visit. 
The refund will be made by the research center when the sponsor indicates it. Prior to the return 
the research center must make a count of the assigned medication and the remaining medication, 
with the aim of creating an inventory which serves for the final filling of the medication return form. 
6.4 Outcome variables. 
6.4.1 Security variables. 
• 
Adverse events 
6.4.2 Efficacy variables. 
6.4.2.1 Primary outcome variables. 
• Clinical remission of acute bacterial conjunctivitis on day 8, defined by the absence of: 
- Conjunctival secretion 
- Bulbar conjunctival hyperemia. 
6.4.2.2 Secondary outcome variables. 
 
• Bacterial eradication, on day 8, in the cultures of patients with positive basal cultures. 
Bacterial eradication will be defined as the absence of bacterial species that were present 
in the culture of the baseline visit. 
• Degree of conjunctival hyperemia during visits 
• Degree of conjunctival secretion during visits 
• Overall investigator rating of clinical changes and symptoms during visits. 
6.4.3 Methods and scales to be used for the measurement of the variables. 
 
The variables and their units of measurement are included in Table 5 Method of measuring 
variables . 
 
Variable 
Unity 
Symbol 
Type 
Method of 
measurement 
 
Overall rating 
 
Degrees 
--- 
C. Ordinal 
Direct observation 
and interrogation 
Bacterial 
eradication 
Colony forming 
units 
UFC 
C. Continuous 
Secretion culture 
Adverse events 
Number of cases 
N 
C. Discrete 
Count 
Conjunctival 
bulbar hyperemia 
Degrees 
--- 
C. Ordinal 
Direct observation 
(Biomicroscopy) 
Clinical referral 
If not 
--- 
Qualitative rated 
Direct observation 
(Biomicroscopy) 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 30 of 59 
 
Variable 
Unity 
Symbol 
Type 
Method of 
measurement 
 
Conjunctival 
secretion 
Degrees 
--- 
C. Ordinal 
Direct observation 
(Biomicroscopy) 
Table 5 Method of measuring variables. 
 The following describes the methods and scales that will be used for the measurement of the 
variables, which are in strict alphabetical order of the procedure: 
6.4.3.1 Biomicroscopy 
It is the procedure by which, with the use of the slit lamp or biomicroscope, the ocular structures 
are evaluated thanks to the characteristics of the light source and the optical power of the 
instrument. A full assessment of the previous segment will be made, which will be recorded in the 
clinical file. 
By means of biomicroscopy bulbar conjunctival hyperemia, conjunctival secretion will be 
evaluated and will serve for the evaluation of adverse events and the global qualification. 
Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red 
appearance secondary to the vasodilation of the conjunctival vessels of variable intensity. He will 
graduate using the Efron scale. [37] The number will be reported in the CRF, according to the rating 
granted, in each of the visits. (See Illustration 1) 
Illustration 1. Efron scale for conjunctival hyperemia. 
 
 
The ocular secretion will be classified as 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The 
number will be reported in the CRF, according to the rating granted in each of the visits. 
The clinical remission in the visits will be evaluated as "Yes" or "No", to report "Yes" it must have a 
grade of "0" in conjunctival hyperemia and "0" in secretion; otherwise, you must report as "No". 
6.4.3.2 Global qualification of the investigator. 
The global qualification of the investigator constitutes the integral judgment of the clinical picture 
of the subject, including signs and symptoms, after a routine ophthalmological evaluation and 
interrogation. It will be classified 0 = cure, 1 = improvement, 2 = no changes compared to before 
starting treatment, 3 = worsened. It will be registered in the CRF in each of the follow-up visits. 
6.4.3.3 Evaluation of adverse events. 
The evaluation of adverse events requires a questioning conducted by the IP and the appropriate 
exploratory techniques for its detection. 
 
Normal 0 
Very slight 1 
Mild 2 
Moderate 3 
Severe 4 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 31 of 59 
 
The IP will register in the corresponding section of the CRF the EA that the subjects of the study will 
present. 
The management of the EAs will be done according to what is described in section 9.3 Adverse 
events. 
6.4.3.4 Sampling of conjunctival secretion for bacterial culture. 
The microbiological study of body tissue and fluid samples allows to establish the etiological 
diagnosis of different infectious diseases. For this reason it is important to guarantee the quality of 
the sample and the information that must accompany it during the process that begins in the pre-
analysis phase, which includes preparation, procurement and transportation, which concludes in 
the analysis of the sample. 
The conjunctival secretion sample will be taken prior to the instillation of any medication (eg 
tetracaine, tropicamide / phenylephrine) or staining (fluorescein, lysine green) required for 
ophthalmologic evaluation. 
You will use the sample taking kit delivered by the sponsor for this purpose. The kit will consist, as 
a minimum, of two test tubes and two sterile swabs. Each tube will have a label with the following 
minimum information: 
- 
Study number: SOPH157-0217 / III 
- 
Initials of the subject 
- 
Subject number 
- 
Visit 
- 
Right Eye or Left Eye (as the case may be) 
Use gloves for this procedure. Take a sample with the swab, use a swab per eye. Rotate the swab in 
the conjunctival cul-de-sac while moving it from the medial to the lateral zone (see Illustration 2). 
Place the swab in the transport medium (sterile tube with screw cap or rubber stopper). Fill in the 
required information on the label of each tube. And perform the same procedure on the 
contralateral eye. 
 
Illustration 2. Conjunctival secretion sampling. 
Fill the requisition form delivered by the sponsor and contact the authorized third party for the 
analysis of the samples, to schedule the collection. The sample should be kept at room temperature. 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 32 of 59 
 
In the CRF it will register as done, in each one of the eyes. The results will be delivered by the third 
party authorized to the IP and the sponsor. 
Once the result of the basal crop has been obtained, the center will register this result in the CRF. 
When you obtain the results of the final crop you will register them in the CRF. And it will mark in 
the box of the CRF the question ¿Bacterial Eradication? If not. The absence of bacterial species that 
were present in the culture of the baseline visit is considered bacterial eradication. 
The authorized third party will be selected by the sponsor and the relevant information will be 
shared with the centers, which will be in the master folder of the study.  
6.4.4 Time of the measurement of variables. 
• 
Measurements in the baseline visit 
• 
Bulbar conjunctival hyperemia 
• 
Conjunctival secretion 
• 
Sampling of conjunctival secretion 
• 
Measurements in visit 1 
• 
Overall rating 
• 
Adverse events 
• 
Bulbar conjunctival hyperemia 
• 
Clinical referral 
• 
Conjunctival secretion 
• 
Final visit measurements 
• 
Overall rating 
• 
Adverse events 
• 
Bulbar conjunctival hyperemia 
• 
Clinical referral 
• 
Conjunctival secretion 
• 
Sampling of conjunctival secretion 
• 
Security call measurements 
• 
Evaluation of adverse events 
 
 
 
 
 
 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 33 of 59 
 
6.5 Schedule and study diagram. 
The baseline visit will be considered on day 1 of the study, the IP will indicate the subject to start 
the application of the products under investigation that same day. If necessary, adjust the scheme 
so that it complies with the 3 applications of day 1; nevertheless, in the event that during the 
opening hours it is not feasible to adjust the 3 applications, the IP will indicate the application of at 
least 2 instillations, with a minimum of 3 hours between them. 
Visit 1 will be performed in relation to the start of treatment on day 5 with a window period of ± 1 
day. The final visit will be made on day 8, with a window period of + 1 day. The security call will be 
made on day 15, with a window period of ± 2 days. 
6.5.1 Timeline  
Process 
B 
1 
Final 
LL. S. 
1 
5 ± 1 
8 + 1 
15   ± 2 
Eligibility criteria 
X 
 
 
 
Informed consent signature 
X 
 
 
 
Pregnancy test (if applicable) 
X 
 
X 
 
General and ophthalmological clinical history 
X 
 
 
 
Comprehensive ophthalmologic exploration 
X 
X 
X 
 
Assignment of subject code 
X 
 
 
 
Assignment to treatment group 
X 
 
 
 
Delivery of medication and start of instillation 
X 
 
 
 
Sampling of conjunctival secretion 
X 
 
X 
 
Biomicroscopy 
X 
X 
X 
 
Global qualification of the researcher 
 
X 
X 
 
Evaluation of concomitant medications 
X 
X 
X 
 
Delivery of the subject's diary 
X 
 
 
 
Evaluation of adverse events 
 
X 
X 
X 
Continuity evaluation 
 
X 
X 
 
Adherence evaluation (per subject's diary) 
 
X 
X 
 
Return of the medication 
 
 
X 
 
Returning the subject's journal 
 
 
X 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 34 of 59 
 
6.5.2 Procedures to be performed per visit. 
Next, the procedures that will be carried out in each visit are listed, as well as a brief description of 
these.  
6.5.2.1 Basal visit. 
▪ 
Eligibility criteria: refers to the review by the IP, where it states that the subject can be 
included in the study by meeting the inclusion criteria and not meeting the exclusion 
criteria. See 6.2 Eligibility criteria. The IP selects the eye that will be included for the efficacy 
analysis, indicating it in the clinical note and in the CRF. 
▪ 
Signature of informed consent: refers to the signing of the written informed consent 
document. See 10.3 Consent 
▪ 
Pregnancy test: refers to the performance of a rapid pregnancy test in all women of age 
who wish to enter the study. By fertile age we understand women who have not had their 
menopause, defined as 12 months since the last menstrual period in women over 40 years 
of age, or who have undergone a bilateral hysterectomy or oophorectomy. Women of 
childbearing age with contraceptive methods including bilateral tubal obstruction should be 
tested for pregnancy. This test will be performed by the IP or the designated team person 
according to the instructions of the device delivered by the sponsor. 
▪ 
General and ophthalmological clinical history: refers to the technical, clinical and legal 
document in which the patient's health conditions, medical acts and other procedures 
performed on the patient are recorded chronologically. It includes the anamnesis and 
comprehensive ophthalmological exploration that allows to discern the patient's eligibility. 
If the patient is taken from the established consultation of the study center, he / she will be 
able to use the existing clinical history, only having to perform an update. 
▪ 
Conjunctival secretion sampling: see section 6.4.3.4 Conjunctival secretion sampling for 
bacterial culture. 
▪ 
Comprehensive ophthalmological exploration: it refers to the evaluation of the ophthalmic 
structures of the subject, eyelids and appendices, ocular surface, anterior segment and 
posterior segment; not considered within the outcome variables. This evaluation has the 
purpose of identifying alterations that may interfere with the course of the investigation or 
identify adverse events. This scan will be recorded in the clinical file, in the CRF only what is 
considered an adverse event will be reported. 
▪ 
Assignment of the subject's code: It refers to granting the number that will identify the 
patient throughout the study. This will be done according to section 6.2.4 Identification of 
the subject.   
▪ 
Assignment to the treatment group: It refers to determining the treatment that the patient 
will follow during the study. It will be done according to section 7. Methods. Assignment of 
the intervention. 
▪ 
Delivery of medication: This refers to the delivery of the medication to the patient of the 
study, by the research center. It will be done according to sections 6.3.1 Managed 
treatments and 6.3.4.1 Delivery and reception. After each medication delivery, training or 
re-training of the application of the study medication will be carried out. 
▪ 
Biomicroscopy: see 6.4.3.1 Biomicroscopy 
 
▪ 
Evaluation of concomitant medications: it refers to the interrogation that the IP of the 
medications that the patient uses, before, during and after the study. They must be 
registered in the corresponding section in the CRF, including name of active substance, 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 35 of 59 
 
posology and duration. See: 6.3.3 Treatments and concomitant interventions allowed and 
prohibited before and during the study. 
▪ 
Subject's journal delivery: refers to the delivery by the IP, of the subject's daily instrument, 
to the subject. 
6.5.2.2 Visit 1  
▪ 
Comprehensive ophthalmological exploration: see 6.5.2.1 Baseline visit. 
▪ 
Biomicroscopy: see 6.4.3.1 Biomicroscopy 
▪ 
Global qualification of the researcher: see 6.4.3.2 Global qualification of the researcher 
▪ 
Evaluation of concomitant medications: see 6.5.2.1 Baseline visit. 
▪ 
Assessment of adverse events: see 6.4.3.3 Evaluation of adverse events 
▪ 
Continuity evaluation: refers to the determination by the PI and desire of the subject to 
continue with their participation in the study. 
▪ 
Evaluation of the adherence: refers to the review of the diary of the subject to evaluate the 
registration of drug application. 
▪ 
Global qualification of the researcher: see 6.4.3.2 Global qualification of the researcher  
 
6.5.2.4  Final Visit 
▪ 
Pregnancy test: see 6.5.2.1 Baseline visit. 
▪ 
Conjunctival secretion sampling: see section 6.4.3.4 Conjunctival secretion sampling for 
bacterial culture 
▪ 
Ophthalmological examination: see 6.5.2.1 Baseline visit. 
▪ 
Biomicroscopy: see 6.4.3.1 Biomicroscopy 
▪ 
Global qualification of the researcher: see 6.4.3.2 Global qualification of the researcher 
▪ 
Evaluation of concomitant medications: see 6.5.2.1 Baseline visit. 
▪ 
Assessment of adverse events: see 6.4.3.3 Evaluation of adverse events 
▪ 
Continuity evaluation: see 6.5.2.2 Visit 1 
▪ 
Adherence evaluation: see 6.5.2.2 Visit 1 
▪ 
Global qualification of the researcher: see 6.4.3.2 Global qualification of the researcher 
▪ 
Return of the medication: refers to the delivery, by the subject, of the excess medication to 
the research center. 
▪ 
Return of the subject's diary: refers to the delivery, by the subject, of the tool "subject's 
diary" to the research center. 
6.5.2.5 Security call: 
▪ 
Assessment of adverse events: see 6.4.3.3 Evaluation of adverse events. 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 36 of 59 
 
6.5.3 Diagram of the study. 
 
Figure 6. Diagram of the study. 
6.6 Sample size. 
The sample size calculated for the present study is 160 eyes. They plan to recruit 160 subjects, each 
one will provide an eye for the study, for the analysis of efficacy. 
Divided into two intervention groups, each group will be comprised of 80 eyes. 
6.6.1 Calculation of the sample size. 
The sample size was calculated using the formula for variables of two proportions, likewise the data 
was entered into the online calculator, software developed in: www.powerandsamplesize.com 
based on Chow S et al. [39] 
Based on the final report of the Phase II clinical study, and the difference found between the 
intervention of PRO-157, three times a day, against gatifloxacin 0.3%, the calculation of the sample 
size was made. 
The dosage that showed the greatest efficacy was the instillation of 1 drop three times a day. A cure 
percentage of 88% was observed with the mentioned group. The group that received Gatifloxacin 
reported a cure rate of 94%. Nevertheless, there was no statistical difference between the groups. 
[35]   
The sample size was calculated considering the clinical cure rate of 0.88 submitted to the 
treatment with PRO-157 1 drop three times a day compared to a percentage of 0.94 of the group 
with Gatifloxacin. It is expected that at least a healing difference of 15% will be present to 
demonstrate superiority in the upper and lower limits, in order to demonstrate non-inferiority. 
The formula for non-inferiority or superiority was used comparing two proportions1 with a Power 
(1-β): 90% and an error type 1, α: 5%. Margin or limit, δ: 15%. 
𝑛= 𝑝(1 −𝑝) (
𝑍1−𝛼+ 𝑍1−𝛽 
𝑝−𝑝0 −𝛿)
2
 
Basal 
(Day 1) 
Visit 1 
(Day 5 ±1) 
Final 
visit 
(Day 8 +1) 
Security Call (Day 15 ± 
2) 
Period of treatment in the study groups: 
- 
PRO-157 
- 
Gatifloxacin 0.3% 
 (7 days) 
P. 
Security 
(7 days) 
(Day 7)          End 
application 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 37 of 59 
 
 
 
 
 
The result is 112 eyes with acute bacterial conjunctivitis. Considering an increase of 30% (15) due 
to the probable losses and a balance between the groups, the final sample size is 160 eyes. 
The intervention will be applied in both eyes, however each subject will only provide one eye for 
efficacy analysis.  
6.7 Recruitment . 
The subjects will be recruited from the IP external consultation or referenced from first level centers. 
Recruitment will be competitive for all centers. 
 
7. Methods Assignment of the intervention. 
7.1 Generation of the allocation sequence. 
2 strata corresponding to the intervention groups will be used, which will be balanced for each 
research center. The allocation will be 1: 1. The generation will be done through an electronic system 
validated by an external provider, previously evaluated and authorized by Sophia Laboratories S.A. 
of C.V. The information corresponding to this provider will be found in the master folder of the 
study. 
7.2 Blinding mechanism. 
Blinding will be performed by the personnel indicated by the Clinical Operations Management of 
Sophia Laboratories, S.A. of C.V. The vials of both interventions will be re-labeled and the secondary 
packaging will be masked. 
7.3 Implementation. 
The sequence will be generated by means of an electronic randomisation system. Said system will 
be hired by Sophia Laboratories, S.A. of C.V. to a third party. The information corresponding to this 
third party will be found in the master folder of the study. 
7.4 Blinding and masking. 
The blinding will correspond to the research subject and the principal investigator. In addition, the 
statistical analysis will be carried out in a blinded manner in the case of a partial and final analysis. 
The masking will be done using boxes in the primary packaging identical in the two groups and 
relabelling the bottles of both interventions. 
Blinding for the research subject and the researcher will be done by replacing the commercial labels 
in the case of the comparator in the bottles and the use of identical labels that contain the 
assignment number. 
7.4.1 Opening of blinding. 
Blinding may be opened in the following cases: 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 38 of 59 
 
1.  Presence of a serious adverse event. 
2.  Safety alarm due to the use of the drugs under study. 
3.  In case the sponsor determines it for any security reason or other reason that it considers 
pertinent. 
 
8. Methods Collection, administration and data analysis. 
8.1 Methods of data collection. 
A clinical monitor will be assigned to each research center, which will be authorized to monitor, 
review, procure and ensure that the quality of the information obtained from the participants is 
reliable and trustworthy. Each monitor will schedule periodic visits to the research centers in order 
to review the source documents and corroborate the information captured in the CRF. All clinical 
monitors will be trained in relation to the information of the study protocol (objective, visits, 
procedures, range of accepted values, etc.). In the event that the data are not identical between the 
two registers, the clinical monitor will generate a discrepancy, which must be resolved by the 
research center in time that the sponsor deems reasonable to meet the objectives of the clinical 
study. The correction of the discrepancies will be made according to the Good Documentation 
Practices.  
The data registered in the CRF will be reviewed by personnel of Sophia Laboratories, trained in the 
ophthalmological, clinical and pharmacological area, which will be able to generate discrepancies in 
the event that the data do not comply with the stipulations of the research protocol. Or put the 
participants at risk. 
Once all discrepancies generated by the team of clinical monitors and clinical staff have been 
resolved, the data will be downloaded into an electronic database (Excel Sheet) by personnel 
designated by the sponsor. A new review of the data will be carried out to corroborate the fidelity 
of the same and new discrepancies may be generated in case it was considered. 
The database generated will be safeguarded by the sponsor and will only have personal access 
designated by the same. 
8.1.1 Strategies to complete the follow-up. 
• 
• You will be clearly informed of the importance of the study and the benefits that the 
population will obtain from the results of the study. 
• 
• Transportation assistance will be provided in order for the participant to attend their visits. 
• 
• A printed calendar will be provided with the objective of reminding the participant of their 
appointments and the activities that will be carried out, in addition to the estimated 
duration of the same. 
• 
• In case the participant does not attend his appointment, the research center must make 
a call to know the reason and try to arrange a new appointment within the established 
window period or an unscheduled appointment. 
• 
• In case it is not possible to make an appointment, it will be asked about the presence of 
adverse events and the reason for leaving the study, such as minimum data. 
8.2 Data management. 
The subject's medical record (including clinical notes, test results, etc.), as well as the subject's diary, 
are considered source data. 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 39 of 59 
 
The IP or the designated person of your team will fill out the Case Report Format (CRF) as well as all 
other documents provided by the sponsor (for example: documents related to the management of 
the treatment). 
An electronic CRF was designed to record the data that are required in the protocol and that the 
researcher collects in each of the visits. 
In the case of self-assessment questionnaires, it is not permissible for the principal investigator or 
person responsible for filling in to modify what was written by the subject of the study. 
The data capture in the investigator's site will be done by the investigator or the designated person 
of his team after performing the Medical File. The researcher or a designated person of your team 
will be trained in filling the CRF. 
All corrections to the CRF data should be made by the investigator or the designated person of your 
team in accordance with the instructions provided. 
To ensure the confidentiality and security of the data, user names and access codes will be used to 
restrict access to the system only to authorized personnel. 
The monitor must ensure that all the data has been filled in the CRF. After comparing the data 
against the source documents, the monitor will ask the researcher to make the necessary correction 
/ clarification, so that they are answered and closed as quickly as possible. 
The Scientific Committee of Sophia Laboratories S.A. of C.V. will give the latest medical-scientific 
review, and will set the standard for freezing the database. 
8.3 Statistical methodology. 
8.3.1 Analysis of primary and secondary outcome variables. 
The statistical analysis will be carried out by personnel of Sophia Laboratories. The statistical 
program SPSS version 19 will be used. 
The designated personnel will be blinded to the intervention groups. The coding will be done using 
consecutive numbers for each intervention group. 
The data will be collected and sorted in an excel sheet. Later they will be exported to the platform 
of the SPSS program. The variables will be categorized according to their nature. 
The result of the continuous quantitative variables will be presented in measures of central 
tendency: mean, standard deviation and ranges. See Table 5 Variable measurement method. The 
total size of the samples will consider an eye as a case for the evaluation of efficacy. Paired samples 
will be considered in cases with visits before and after the intervention. 
The normal distribution of results will be obtained through the Kolmogorov-Smirnov and Shapiro-
Wilks test, as applicable. 
The statistical analysis of the continuous quantitative variables to find significant differences (p) will 
be the following:  
• 
Inter-group analysis: t test for paired samples.   
The level of difference to consider significance will be of an alpha of 0.05 or less.  


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 40 of 59 
 
The result of nominal and ordinal qualitative variables will be presented in frequencies, proportions 
and percentages. See Table 5 Method for measuring variables . 
The statistical analysis to identify significant differences of the qualitative variables will be done by 
creating 2x2 contingency tables and will be done as follows:  
• 
Difference between groups: χ2 test (Chi-square) of Pearson or Fisher's exact in 
expected values less than 5. 
The level of difference to consider significance will be an alpha of 0.05 or less. 
For the reporting of adverse events all participating subjects who were randomly assigned 
to an intervention group will be considered. The results will be expressed in number of subjects. 
The final report of the results will be shown in tables or graphs, as appropriate. 
In case of loss of cases (data), they will not be replaced by any situation to complete the 
sample size. 
According to the data obtained, the sponsor will decide to perform a subanalysis by age 
groups, which will have no influence on the final result. 
8.3.2 Additional analyzes. 
An internal analysis will be made to know the changes that occur between each visit. It is the 
sponsor's prerogative to request an additional analysis of the data, during the conduction of the 
study or at the end of this.  
8.3.3 Population analysis and management of missing data. 
The effectiveness analysis will consider those cases in which the measurements of the baseline and 
final visit are met. Those subjects who do not comply with any of these measurements will not be 
integrated into the final database to evaluate the effectiveness. Nevertheless, an intention to treat 
analysis (ITT) will be carried out. 
The safety assessment will include in the analysis all those subjects (considering one eye or both) 
who have been exposed at least once to any of the interventions regardless of the visit in which they 
were eliminated from the study. 
9. Methods Monitoring. 
 
9.1 Data monitoring. 
Monitoring visits by a site monitor from Sophia Laboratories, S.A. of C.V. are intended to confirm 
that the studies sponsored by Sophia Laboratories, S.A. of C.V. they are conducted in accordance 
with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent 
with Good Clinical Practices and with the applicable regulatory requirements (verifying a continuous 
compliance with the protocol, amendment or amendments, reviewing accounting records of the 
product under investigation, verifying that the personnel of the site and the facilities remain 
adequate to carry out the study). 
The researcher must ensure that they have sufficient time, space and qualified personnel for the 
monitoring visits. 
In order to carry out the monitoring review, it is mandatory to provide direct access to all source 
data and those related to the study site. The monitor will conduct a review of the CRF and a 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 41 of 59 
 
Verification of Source Documents (VDF). By VDF means the verification of the records in the CRF 
through its comparison with the source data that the researcher will make available for this purpose. 
Regarding the CRF, the monitor will mark the screens completed and approved at each visit. 
In accordance with the applicable regulations, Good Clinical Practices, and the procedures of Sophia 
Laboratories, S.A. of C.V. The monitors of Sophia Laboratories, S.A. of C.V. will contact the site before 
the start of the study to review the protocol, the regulatory and ethical requirements of Sophia 
Laboratories, S.A. of C.V. with the staff of the site. When reviewing the procedures for data 
collection, the conversation will also include the identification, agreement and documentation of 
the individual data for which the records in the CRF serve as source documents. 
Sophia Laboratories, S.A. of C.V. monitor the study to verify, among other things, that: 
 
• 
The data is authentic, correct and complete. 
• 
The safety and rights of the subjects are being protected. 
• 
The study is being conducted in accordance with the currently approved protocol, any other 
study agreement, Good Clinical Practices and all applicable regulatory requirements. 
 
 
The investigator and the head of the medical institution (when applicable) agree to allow the 
monitor to have direct access to all relevant documents. 
Study monitoring visits will be conducted at regular intervals, depending on the recruitment rate, 
under the arrangements between the investigator and the sponsor. All information related to these 
visits will be handled as strictly confidential. 
 
Upon completing or discontinuing the study prematurely, the monitor will carry out site closure 
activities with the investigator or site staff, as appropriate, in accordance with applicable 
regulations, Good Clinical Practices, and Sophia Laboratories SA of C.V. procedures. 
 
After the study is closed, the researcher must keep all study records on the site in a safe place. 
Records should be maintained to allow easy and timely recovery, when necessary (for example, in 
an audit or inspection). Sophia Laboratories, S.A. of C.V. will inform the investigator / institution the 
period of time they will have to retain these records, in order to comply with all applicable regulatory 
requirements. However, the investigator / institution must seek the written approval of the sponsor 
before proceeding to the elimination of these records. The minimum retention time will satisfy the 
most stringent standard applicable to that site for the study, in accordance with the provisions of 
the PCBs, any institutional requirements or the applicable laws or regulations, or the standards / 
procedures of Sophia Laboratories, S.A. of C.V. 
 
The researcher / institution must notify Sophia Laboratories, S.A. of C.V. Of any change in file 
arrangements including, without limitation, the following: file in an off-site facility, ownership 
transfer of records in the event the investigator leaves the site. 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 42 of 59 
 
9.2 Preliminary analysis and early termination of the study. 
The partial analysis will allow the sponsor to make a decision about the early termination of the 
study in the event that the safety of the participants is compromised. 
The early termination of the study will be considered in the following cases: 
1.  Presence of serious adverse events in more than 5% of the participants in each intervention 
group. 
2.  The competent authority considers it for security alerts. 
3.  The Sponsor determined it for his convenience or eventualities such as: economic support, 
manufacturing errors, etc. 
4.  Lack of recruitment as expected.  
In case the decision is the early termination of the clinical study, all the research centers will be 
informed within the first 24 hours by the available communication channels. Likewise, the 
corresponding authority in each country will be informed (if applicable) and the Ethics Committees 
involved. 
Each research center has the obligation to inform the subjects that participate in the clinical study 
in a period no longer than 24 hours, after receiving the information from the sponsor. You must 
inform all the subjects involved in any phase of the study. 
The result of the preliminary evaluation will be in charge of the Clinical Operations Management 
and the Medical Management of Sophia Laboratories, S.A. of C.V., which will have the faculty to 
determine the fate of the present protocol, as they deem convenient. 
9.3 Adverse events. 
9.3.1 Responsibilities of the Investigator. 
Perform the verification of adverse events through questioning, relevant physical examination, 
assessment of evolution, as well as adequate medical and pharmacological management, resolution 
or outcome and final discharge following the definitions determined in national and international 
regulations. [40] [41] [42] 
In case of adverse events or any event that puts the health and well-being of the patients at risk, 
appropriate medical attention will be provided, either at the research site or will be referred to the 
Hospital Center with greater resolving power with which the research site and / or researcher have 
medical care agreement. The researcher will notify the clinical monitor of the sponsor, according to 
the times established in the national and international regulations. In the case of serious adverse 
events, notify the sponsor and record the corresponding information in the case report form and in 
turn inform the Research Ethics Committee, the Research Committee.  
The attention of the adverse events will be made according to the diagram of attention of the event 
(see Figure 7. Attention of the adverse event) 
In the final report to be drafted by the Scientific Committee of the Department of Clinical Operations 
of Sophia Laboratories, S.A. of C.V., will include the report of adverse events in compliance with 
current national and international regulations. [40] [41] 
9.3.1.1 Record of adverse events in the Case Report Form. 
The registry of adverse events considers the information concerning the identification data of the 
participating patient as code, age, sex, left eye, right eye.  


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 43 of 59 
 
Information about the type of adverse event, adverse reaction or suspected adverse reaction to the 
product under investigation or to the study medication, as appropriate. The date on which the 
adverse event occurs is reported, as well as in which the Investigator is aware of it, date of resolution 
or outcome, as applicable. The clinical diagnosis is indicated. If a lack of therapeutic response is 
detected to the investigational product and / or investigational medication, it should be reported as 
an adverse reaction. Include in concomitant medications the therapy used for the pharmacological 
management of the adverse event, suspected adverse reaction, adverse reaction. Record the 
outcome or resolution of the event: patient recovered without sequelae, with sequelae, not 
recovered. Patient who presented death due to adverse reaction / adverse event, patient who 
presented death and it is judged that the drug could have contributed, patient who presented death 
and this is not related to the investigational product or drug, or indicate that it was not knows what 
the consequence of the event is.  
Consign information about the product or drug under investigation or the drug associated with the 
adverse event, adverse reaction or suspected adverse reaction. As applicable, information 
concerning generic denomination, distinctive denomination or product code in research and / or 
investigational medication should be recorded, as appropriate according to the methodological 
design of the study, this is relevant in the case of blinded studies or those where they use placebo 
as comparators, since there are circumstances that justify opening the cecum to determine if the 
adverse event, the adverse reaction or suspected adverse reaction may be attributable to the active 
agent, the combination of active agents, or the substance (s). s) pharmacologically inert (s), such as 
vehicles or additives, as appropriate to the clinical research phase in which the development of the 
drug is located.  
It will also be necessary to record the data concerning a) batch number, b) manufacturer laboratory, 
c) expiration date, d) dosage, e) route of administration, f) start dates and g) term of administration 
and / or consumption , reason for the prescription; according to whether it is a product or 
investigational medicine (protocol in which the patient currently participates) or is a medicine that 
the subject under investigation consumes for the treatment of basic concomitant diseases or used 
for the management of any sign or transient symptom that does not correspond to the Natural 
History of the pathology that motivated its entry into the research protocol.  
Record the withdrawal or maintenance of the medication, investigational product or investigational 
medication, as appropriate. Indicate if the adverse event disappears when the investigational 
product or investigational medication or suspicious medication is removed (to provoke the event). 
Also indicate if a dose adjustment is made, if the event changes in terms of intensity or seriousness, 
persistence of the reaction. It is important to indicate that in those patients who are exposed again 
to the investigational product, investigational medication or medication, which had previously been 
suspended, if the adverse reaction or adverse event reappears.  
Regarding concomitant pharmacotherapy. Indicate the generic name, the dose, the route of 
administration, start and end dates of its use, as well as the reason for the prescription regardless if 
it is consistent with the information to prescribe or technical data sheet or is used outside the 
regulations or of what the local, national or international regulatory entity has authorized. 
Concerning the relevant clinical antecedents. The analysis of the adverse event, adverse reaction or 
suspicion of adverse reaction considers the information previously reported, notwithstanding the 
clinical context in which said harmful phenomenon occurs in the participants of the clinical research 
protocol, it is of special interest, so that the information about previous ailments, hypersensitivity 
or allergy phenomena, previous surgical procedures, laboratory analysis or cabinet exams that have 
been practiced on the participant, etc.., that the researcher deems convenient to mention may do 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 44 of 59 
 
so. If you have enough space in the case report format, you can complement the information in your 
clinical note of the clinical file. 
9.3.1.2 Follow up of adverse events. 
The IP will provide the attention and guidance of the EA that the participant presents until the end 
of the same, according to what is referred to the following section. 
9.3.1.3 Procedures for a serious adverse event. 
The process of attention of the adverse event considers the following stages: 
 
Figure 7. Adverse event attention. 
A. During the development and conduct of the present clinical investigation, undesirable 
damaging events or adverse reactions, of medical involvement, which do not necessarily 
have a causal relationship with the investigational product or investigational drug, may 
occur in the participant patient. These harmful phenomena can occur during the use of 
investigational drugs, unintentionally, at doses authorized for use in humans; by a local, 
national or international regulatory entity, whether for prophylaxis, diagnosis, treatment or 
for the modification of some physiological process. However, it can be suspected that the 
investigational product or the investigational drug or the placebo cause some unwanted 
clinical manifestation. Adverse events, adverse reactions or suspected adverse reactions to 
one or several medications can occur during the systematic evaluation of the participants 
(on the days when the clinical review is scheduled, according to the schedule of activities) 
or suddenly, as such way that,  
B. The investigator must be the first person to whom the patient notifies that they have 
developed or presented a harmful clinical phenomenon during their participation in this 
research protocol. 
C. According to their clinical judgment; on the basis of the pertinent physical examination, 
interrogation, etc., as well as the analysis of the information available in the medical 
literature and that referred to in the investigator's manual, information to prescribe or 
technical data sheet of the comparator drug, the principal investigator determines the 
relevant attention of the event / harmful reaction; either:  


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 45 of 59 
 
D. In the research site or in the hospital with the greatest resolving power (1st, 2nd or 3rd level 
of medical attention). In such a way that, in case the patient is sent by the Investigator to a 
hospital, he / she attends by means of a reference system, it can be with an identification 
card that the patient belongs to the present investigation and there is an official number or 
folio, which pertains to the emergency care agreement with the health institution with the 
greatest resolving power, or a medical reference note issued by the principal investigator, 
so that appropriate care is given to the participating patient. It should be noted that the 
Study Sponsor, Sophia Laboratories, S.A. of C.V., will pay the expenses for the medical care 
of the participating patient, only if the adverse event, adverse reaction or suspected adverse 
reaction to medication is associated or found in relation to the investigational product or 
investigational drug. 
E. Taking the clinical information gathered, either during the care provided in the research site 
or provided by the treating physician (s) in the hospital, the principal investigator records 
the adverse event, suspected adverse reaction or adverse reaction to medication in your 
clinical note of the clinical file, indicating the seriousness, intensity (mild, moderate or 
severe), relationship with the product or investigational medicine, as well as: 
F. The migration of the relevant data to the case report format and to its respective adverse 
event section; noting the pertinent information, already referred to in section 9.3.1.1., this 
in virtue of the fact that in cases of serious adverse events, which must be notified in less 
than 24 hours after the moment in which the principal investigator has knowledge of the 
same, the clinical monitor of the study is informed, so that in turn he / she informs the 
Scientific Committee and the Pharmacovigilance Department of the sponsor and later he / 
she informs the Research Ethics Committee. Regarding non-serious adverse events, these 
will be recorded and adequately addressed and the corresponding regulatory entity will be 
informed about the safety profile of the product under investigation or investigational 
medication in the final report of the clinical trial. 
The record of the outcome of the adverse event, suspicion of adverse reaction or adverse reaction 
to medication depends substantially on the follow-up that the principal investigator makes to the 
participant, since most of the harmful phenomena are expected, consult section of the safety profile 
in number 5.3 and in the researcher's manual, they are ophthalmic in nature, however there may 
be systemic alterations. Therefore, in the opinion of the researcher, the withdrawal of the 
participant or his / her permanence will be considered, according to the stipulations of section 6.2.3 
Elimination criteria of this research protocol. 
 
 
 
9.3.1.4 Causality evaluation. 
 
The assessment of the causality, the methodology used to estimate the probability of attributing to 
a drug, investigational drug or investigational product the adverse reaction, the suspicion of the 
same or the observed adverse event, considers probabilistic categories, according to the evidence 
available and the quality of information, based on national pharmacovigilance regulations. [40] As 
a tool to facilitate the probabilistic categorization of causality, the principal investigator can use the 
algorithm of Karch and Lasagna modified by Naranjo referred to by Aramendi I, 2011 in which 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 46 of 59 
 
different items are qualified which allow assigning a value to the relationship cause-effect between 
the administration of the drug and the adverse reaction. [43]  
Table 6. Algorithm of Karch and Lasagna modified by Naranjo. 
No. 
Reagents 
Yes         No 
1. 
There are previous conclusive reports about the adverse drug reaction, adverse event 
or suspected adverse drug reaction 
+1 
0 
2. 
The adverse event appeared when the suspected drug was administered 
+2 
-1 
3. 
Adverse reaction to medication, adverse event or suspected adverse drug reaction 
improved upon discontinuation or administration of a specific antagonist 
+1 
0 
4. 
Adverse reaction to medication / adverse event / suspected adverse drug reaction 
reappeared when administering the drug / investigational product / investigational 
medication 
+2 
-1 
5. 
There are alternative causes that may cause this reaction 
-1 
+2 
6. 
Adverse reaction / adverse event / suspected adverse drug reaction occurred after 
placebo administration 
-1 
+1 
7. 
The drug was determined in blood or other liquids in toxic concentrations 
+1 
0 
8. 
The intensity of the adverse reaction / adverse event / suspected adverse drug reaction 
was higher with higher doses or lower with lower doses 
+1 
0 
9. 
The patient has had similar reactions with the drug / product under investigation or 
investigational medication, in the past 
+1 
0 
10. 
Adverse reaction / adverse event / suspected adverse reaction to medication was 
confirmed with some objective evidence 
+1 
0 
                                                                                                                               Total score 
summation 
Probabilistic category based on the score obtained 
I 
The causal relationship is checked 
≥,9  
II 
It is likely that ADR is due to the drug or product under investigation 
5 a 8 
III 
It is possible that the RAM is due to the drug or product under investigation 
1 a 4 
IV 
The causal relationship is doubtful 
0 
The reagents considered by the algorithm of Karch and Lasagna modified by Naranjo where each one receives a defined 
score are shown and the final summation allows estimating the probabilistic category of the cause-effect relationship 
between the administration of the drug / product in research / investigational medicine and the adverse reaction, 
adverse event or suspected adverse reaction. Consider that if the information is not available, a score equal to zero is 
recorded.  
In such a way that the degree of certainty to establish the investigational product or investigational 
medication (as appropriate) as the causal agent of the harmful phenomenon that befalls the 
participating patient, can be directly indicated by the principal investigator based on his or her 
clinical experience or well through the voluntary application of the tool mentioned previously. 
Notwithstanding, it is important that the researcher take into account the following arguments in 
favor of the causal relationship: the strength of association that refers to the number of cases in 
relation to those exposed. The consistency of the data, ie the presence of a common characteristic 
or pattern. The exposure-effect pattern: which determines the relationship with the site of 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 47 of 59 
 
appearance, time, dose and reversibility after suppression. The biological plausibility: that refers to 
the possible pharmacological or physiopathological mechanisms involved in the development or 
presentation of the adverse event. Experimental findings: for example the appearance of anomalous 
metabolites or high levels of drug or the product of its biotransformation. Analogy: experience 
acquired with other related drugs, adverse reactions frequently produced by the same family of 
pharmacological agents. Nature and characteristics of the data: objectivity, accuracy and validity of 
the relevant documentation. [44] 
9.3.2 Responsibilities of the sponsor. 
The sponsor will be responsible, and will cover the expenses derived from the medical attention to 
adverse events related to the product under investigation. 
9.4 Audit 
To guarantee compliance with the PCBs and with all applicable regulatory requirements, Sophia 
Laboratories S.A. of C.V. could carry out a quality assurance audit. Regulatory agencies could also 
carry out a regulatory inspection of this study.  
9.4.1 Pre-study audit. 
The research centers included in the study will be subject to a feasibility visit prior to the selection 
of the center, where it will be verified that they meet the minimum requirements indicated by the 
sponsor. 
9.4.2 Audit / Inspection during the conduction of the study. 
They may take place at any time before, during or after the conclusion of the study. If an audit or 
inspection is performed, the investigator and the institution should agree to allow the auditor / 
inspector direct access to all relevant documents, and will allocate their time and that of their staff 
to the auditor / inspector to discuss the findings and any relevant problems. 
 
10. Ethical considerations. 
10.1 Approval of the committees. 
The present study will be conducted according to the standards of the Declaration of Helsinki, World 
Medical Association 2013. Nuremberg Code; Nuremberg Trial by the International Court of 
Nuremberg, 1947. Belmont Report, National Commission for the Protection of Subjects of 
Biomedical Research and Conduct, 1979. 
It will be conducted in accordance with the scientific and technical requirements necessary for the 
registration of medicines for human use of the International Conference on Harmonization (The 
International Council for Harmonization, ICH for its acronym in English) Guide to Good Clinical 
Practices. International Ethical Guidelines for Biomedical Research in Human Beings of the Council 
for International Organizations of Medical Sciences (Council for International Organizations of 
Medical Sciences, CIOMS, 2002). International Ethical Guidelines for Epidemiological Studies of the 
Council for International Organizations of Medical Sciences (Council for International Organizations 
of Medical Sciences, CIOMS, 2008).  
The Research Ethics Committee and the Research Committee will evaluate the protocol before 
conducting the study and will issue their approval or possible modifications for its realization, these 
Committees should be notified of any significant changes to the protocol. In addition to the above, 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 48 of 59 
 
the current regulations issued by the Ministry of Health will also be complied with. General Health 
Law, NOM 012 Official Mexican Standard NOM-012-SSA3-2012, which establishes the criteria for 
the execution of research projects for human health. The study is considered as an investigation 
with a risk greater than the minimum according to the Regulation of the General Health Law on 
Health Research, Title Two, Chapter I, Article 17, Category III, published in the Official Gazette on 6 
January 1987. 
The principal investigators or study coordinators or personnel authorized by the sponsor will be 
evaluated by the Research Ethics Committees, Research Committees, and when applying to the 
Biosafety Committee the essential documentation of the research project: research protocol, letter 
of informed consent, researcher's manual, subject's diary, as well as those requested, in addition, 
according to local, national or international requirements applicable by regulatory entities. 
The study will not start in the research site if you do not have the confidentiality agreements and 
economic proposal of each of the principal investigators, duly signed and without having previously 
obtained the favorable opinion and / or the approval of the Committees of Ethics in Research, 
Research Committees, and when applicable by the Biosafety Committee, corresponding.  
 
The study will not begin without having met the relevant local, national or international regulatory 
requirements and without having the corresponding health authorization. 
10.2 Amendments to the protocol. 
 
The amendment procedure will be pertinent when there is a need to make any change to a 
document that is part of the research project or protocol, derived from variations in the 
methodological structure that affects driving and results, substitution of the principal investigator 
or identification of risks in the research subjects. The documents susceptible of amendment will be: 
protocol, letter of informed consent, researcher's manual, documents for the patient, scales of 
measurement and schedule of activities. 
 
Any amendment must be approved by the sponsor and / or the principal investigator, the amended 
document (s), once reviewed and approved by the Research Ethics Committee and the Research 
Committee or when applicable, by the Committee of Inquiry. Biosafety, (entities that issued the 
initial favorable opinion for the conduct of the investigation) will be sent (s) for authorization by the 
relevant regulatory entity. 
 
Amendments that substantially modify the protocol or confer an additional or different risk to the 
research subjects must be approved by the Committee. It is the investigator's responsibility to take 
action in situations that require immediate action to avoid unnecessary harm to study participants. 
 
The principal investigator has the responsibility to inform the Research Ethics Committee of any 
amendment to the protocol that could eventually affect the rights, safety or welfare of the research 
participants. Likewise, he must know any situation or new knowledge that shows a greater risk for 
the participants, the termination or premature suspension of the study, the reasons and the results 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 49 of 59 
 
obtained up to that moment. You must also inform about the conclusion of the study, when 
completing the research protocol. 
The list of amendments, and in the necessary cases, the relation of the issuance of errata, will be 
referred to in the final report of the investigation. 
10.3 Consent 
10.3.1 Obtaining 
Informed consent must be obtained before the subject undergoes any procedure indicated in the 
protocol. 
The written consent documents will incorporate the elements of informed consent described in the 
Declaration of Helsinki and the ICH Guide to Good Clinical Practices and will be in compliance with 
all applicable laws and regulations. 
The IP will provide the potential participant with all the information regarding the characteristics of 
the study, its potential benefits, risks, objectives and procedures thereof. 
This information will be with a language understandable to the subject, it will be explained to the 
subject that has the right to interrupt their participation in the study at any stage, without affecting 
the relationship with the researcher and / or their future assistance. The informed consent will be 
put to the consideration of the possible participant; This must have enough time to analyze each 
and every one of the aspects mentioned above and if there is any doubt this will be clarified by the 
person in charge of obtaining the informed consent. Once the participant agrees to participate in 
the study, he / she must sign and date the informed consent letter in the presence of two witnesses 
who have or are not related to the subject of study, who will participate during the informed consent 
process and will sign endorse that the process was carried out prior to any study procedure, that 
the information of the study was clearly explained and doubts were clarified in case of existing. 
If a subject is illiterate, the acceptance will be with their fingerprint, and in the event that the subject 
is not able to grant an informed written consent, a representative of the "legally authorized" subject 
can provide such consent. The subject in accordance with applicable laws and regulations. 
The IP must also sign and date this consent. 
The informed consent must be signed in duplicate by all involved, and two witnesses, one copy will 
be filed in the file of the subject and the other will be delivered to the participant. The PI must 
document in the patient's medical history, the date on which he signed the informed consent. 
10.3.2 Special considerations. 
In the case of minors (<18 years) it will be necessary to obtain the informed consent of the parents; 
and for minors, over 7 years of age or who, in the opinion of the researcher, show sufficient 
understanding, they must be accompanied by the informed consent. 
10.3.2.1 Informed consent of parents. 
The parents of minors, who can potentially be included in the study, must give their informed 
consent for the participation of their children. This will be documented in the "Informed Consent 
for Parents", which must include the signature of both parents. If the document does not have the 
signature of both parents, it will be considered invalid; only the signature of a single parent will be 
allowed in the following cases: 
- In the case in which the father or mother does not share parental authority with their counterpart 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 50 of 59 
 
- In the case in which the minor has been registered with only one parent 
- In the case in which the minor is an orphan of a father or mother. 
10.3.2.2 Informed consent. 
Minors over the age of 7 must give their consent to participate in the study, which must be 
registered with their signature on the document "informed consent". If the researcher deems it 
advisable to include the consent of a child under 7 years of age, since he considers that he has 
sufficient understanding, he may attach it. Nevertheless, it will be obligatory for all those over 7 
years of age to have their consent, together with the consent of their parents. 
10.3.3 Modification to informed consent. 
 
Any change to "informed consent", "informed consent for parents" and "informed consent" 
constitutes an amendment to these documents and must be presented for approval before the 
Ethics in Research Committees, and if applicable before the Competent Authorities. 
The amendment will include a copy of the new version in the language or languages of the country. 
Such amendments may be implemented only after having obtained the written approval of the 
corresponding committees and the Regulatory Entity (as applicable), with the exception of an 
amendment that is required to eliminate an immediate danger for the subjects of the study. 
Each subject affected by the amendment must complete, date and sign two originals of the new 
version. The subject will be given a signed original of the amendment and the researcher will keep 
the second original. 
10.4 Confidentiality 
 
 
All documents and information provided to the researcher by the sponsor are strictly confidential. 
The researcher expressly agrees that the data on their professional and clinical experience, provided 
to the sponsor on paper and stored electronically or digitally, are only for use related to their 
activities with the sponsor of clinical studies, in accordance with Good Clinical Practices. The 
researcher accepts that he / she and the members of his team will use the information only within 
the framework of this study, to carry out the protocol. This agreement is mandatory as long as the 
confidential information has not been disclosed to the public by the sponsor. The protocol of the 
clinical study provided to the researcher may be used by him and by his colleagues to obtain the 
informed consent of the subjects for the study. The clinical trial protocol, like any information taken 
from it, should not be disclosed to other parties without the written authorization of the sponsor. 
  
The researcher will not reveal any information without the prior written consent of Sophia 
Laboratories, S.A. of C.V., except to the representatives of the Competent Authorities, and only by 
request of the same. In the latter case, the researcher undertakes to inform Sophia Laboratories 
S.A. of C.V. before revealing the information to these authorities. The researcher will fill out and 
maintain a record of the subjects' selection, as well as the identification and enrollment list of each 
of the subjects participating in the study. The researcher agrees to give on-site access to the auditor 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 51 of 59 
 
and / or the representatives of the Competent Authorities. The information will be treated in 
compliance with professional secrecy. 
10.5 Deviations  
A deviation is any alteration in the procedures and activities described in the research protocol 
approved by the committees and regulatory authorities. They may be the product of modifications 
or omissions, which may compromise the safety of the participants or the quality of the data 
generated.   
Major deviation / violation: is one that impacts one or more of the following aspects: 
- Subject security 
- Alteration of the risk-benefit balance 
- Commit the integrity of the study data 
- It affects the voluntariness of the subject in the participation of the study. 
The list of examples cited below serves the purpose of guidance, but does not cover all possible 
cases, so it is not limiting: 
I. 
In relation to informed consent: 1) that informed consent has been taken by an 
unauthorized person to do so, 2) that the subject under investigation signs a version of 
informed consent not approved by the committees and regulatory entity, 3) that perform a 
study procedure prior to signing informed consent. 
II. 
Regarding the inclusion / exclusion criteria: 1) enroll subjects who do not meet all the 
inclusion criteria and / or meet any exclusion criteria, 2) enroll defined subjects as part of 
the so-called vulnerable population: children, pregnant women, prisoners, without prior 
approval for such group; 3) Enroll patients before the start or after the end of the study. 
III. 
 In relation to the medication of the study: error in the delivery or dosage of the same. 
IV. 
In relation to concomitant medication: use of prohibited medication. 
V. 
In relation to the study procedures: that those that, in the opinion of the principal 
investigator, compromise the safety of the research subject are not carried out. 
VI. 
In relation to the reporting of serious adverse events: those that are reported outside the 
time stipulated by the committees.  
Minor deviation: is that which does not impact on the safety of the subject, does not alter the risk-
benefit balance, does not compromise the integrity of the study data or does not affect the subject's 
willingness to participate in the study. 
The list of examples cited below serves the purpose of guidance, but does not cover all possible 
cases, so it is not limiting: 
 
I. 
Oblivion in the taking of the study medication. 
II. 
Lack of return of study medication by the subject. 
III. 
 Visits of the research subject carried out outside the window. 
10.5.1 Management of deviations. 
 
All deviations must be reported by the IP to the sponsor and the corresponding committees. 
At your discretion, and depending on the severity of the deviation, the sponsor and the 
corresponding committees may: 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 52 of 59 
 
- Request more information. 
- Citing the principal investigator and / or the members of his team. 
- Temporarily suspend the researcher for present and / or future investigations until the 
situation is resolved and / or considers the explanations given by the person (s) responsible 
for the deviation satisfactory. 
Conduct an audit for cause. 
10.6 Declaration of interests. 
The researchers who collaborate in the present study (principal investigator, subinvestigator) 
commit themselves to carry out, prior to the beginning of the study, a statement of financial 
interests, as well as conflict of interest. 
10.7 Access to information. 
The final database of the study will be owned by Sophia Laboratories, S.A. of C.V. and your access 
will be restricted. The IP will not have access to it, unless it has prior written authorization from the 
sponsor. 
10.8 Auxiliary care and after the end of the study. 
The care of the EAs will be done according to section 9.3 Adverse events. 
10.9 Biosecurity aspects. 
Inappropriate manipulation of the conjunctival secretion sample can become a source of biological 
risk for people who are in contact or for the environment. Therefore, for the protocol titled: "Clinical 
study of the efficacy of the ophthalmic solution of Pazufloxacin 0.6% (PRO-157) for the treatment 
of acute bacterial conjunctivitis, compared to the ophthalmic solution of Gatifloxacin 0.3%." And 
number: SOPH157-0217 / III, is urged to take BASIC BIOSECURITY MEASURES, due to the handling 
of infectious-contagious biological material of relative danger. 
Use the necessary personal protection elements to avoid exposure with biological risk: 
• Gloves. 
• Coat. 
• Leak-proof and easy-to-seal container. 
In case of accident with biological risk, it is recommended to clean with soap and water from the 
area of the exposed body, not touch your own eyes until you have thoroughly cleaned the exposed 
area or follow the recommendations of the institutional guide of the work accident with biological 
risk.  
10.10  Final report and publication of results. 
10.10.1 Final report. 
Once the statistical analysis is finished, a final report will be drafted with the results obtained, in 
charge of the Scientific Committee of the Department of Clinical Operations of Sophia Laboratories, 
S.A. of C.V. Said report will be prepared following the recommendations of the E3 Step 4 Guide of 
the ICH. 
10.10.2 Communication of results. 
Sponsor's plan to communicate the results of the study to researchers, participants and regulatory 
entities. 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 53 of 59 
 
Regardless of the results in the study, Sophia Laboratories, S.A. of C.V., is committed to 
communicating the final report of the study to the principal investigators and to the regulatory 
entities corresponding to the countries with participating research centers. Maintaining at all times 
the rights on the publication and dissemination of the information contained.  
10.10.3 Publication of the results 
Sophia Laboratories, S.A. C.V., acting as the sponsor of the study, assumes full responsibility for its 
function and retains exclusive ownership rights over the results of the study, which may be used in 
the manner it deems appropriate. 
Because the study is multicentric, the first publication should be made only with data collected from 
several centers and analyzed under the responsibility of Sophia Laboratories S.A. of C.V. The PI 
undertakes not to publish or communicate data collected only in a center or in part of the centers 
before the publication of the full results of the study, unless prior written agreement is given by 
Sophia Laboratories S.A. of C.V. 
Any publication and / or communication project related to the study and / or the results obtained 
during the study or after the completion of the study will be presented to participating medical 
researchers at least 30 days in the case of a publication and 15 days in the case of a summary, before 
the scheduled date for the communication and / or presentation of a publication. He or the medical 
researchers will comment on the project within 15 days in the case of a publication and 7 days in 
the case of a summary, from the date on which the project is received. 
Nevertheless, in case the sponsor is in the process of submitting a patent application on the results 
of the study, the sponsor may delay its publication or communication of the results of the study 
until the date of registration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 54 of 59 
 
 
 
 
 Page left intentionally blank


 
 
11. References 
 
[1]  American Academy of Ophthalmology, "Conjunctivitis. Preferred Practice Pattern," AAO, San 
Francisco, CA., 2016. 
[2]  B. Udeh, J. Schneider and R. Ohsfeldt, "Cost effectiveness of a point-of-care test for adenoviral 
conjunctivitis," Am J Med Sci, vol. 336, no. 3, pp. 254-264, 2008.  
[3]  J. Rubenstein, "Disorders of the conjunctiva and limbus.," in Yannof M & Duker JS (eds) 
Ophthalmmology, St Louis, MO, Mosby, 1999, pp. 12-18. 
[4]  M. Mannis and R. Plotnik, "Bacterial conjunctivitis," in Tasman M & Jaeger EA (eds) Duane's 
clinical ophthalmology, vol 4., Philadelphia, PA, Lippincott, Williams & Wilkins, 2005, pp. 1-11. 
[5]  G. Hovding, "Acute bacterial conjunctivitis," Acta Ophthalmol, vol. 86, pp. 5-17, 2008.  
[6]  F. Gigliotti, W. Williams, F. Hayden and J. Hendley, "Etiology of acute conjunctivitis in children," 
J Pediatr, vol. 98, pp. 531-536, 1981.  
[7]  C. Fitch, R. Rapoza, S. Owens, F. Murilo-Lopez and e. a. Johnon, "Epidemiology and diagnosis 
of acute conjunctivitis at an inner-city hospital.," Ophthalmology, vol. 96, pp. 1215-1220, 1989. 
[8]  K. Aoki and Y. Tagawa, "A twenty-one year surveillance of adenoviral conjunctivitis in 
Sapporo," Int Ophthalmol Clin, vol. 42, pp. 49-54, 2002.  
[9]  J. Dart, "Eye disease at a community health centre," Br Med J, vol. 293, pp. 1477-1480, 1986.  
[10] P. McDonell, "How do general practitioners manage eye disease in the community?," Br J 
Ophthalmol, vol. 72, pp. 733-736, 1988.  
[11] A. Sheikh and B. Hurwitz, "Topical Antibiotics for acute bacterial conjunctivitis a systematic 
review," Br J General Prac, vol. 51, pp. 473-477, 2001.  
[12] H. Everitt, P. Little and P. Smith, "A randomised controlled trial of management strategies for 
acute infective conjunctivitis in general practice," Br Med J, vol. 333, pp. 321-324, 2006.  
[13] R. Rietveld, G. Riet, P. Bindels, D. Bink and e. al, "The treatment of acute infectious 
conjunctivitis with fusidic acid: a randomised controlled trial," Br J General Pract, vol. 55, pp. 
924-930, 2005.  
[14] R. Kowalski and M. Roat, "Normal flora of the human conjunctiva and eyelid," in Tasman M & 
Jaeeger (eds) Duane's clinical ophthalmology, vol2., Philadelphia PA, Lippincott, Williams & 
Wilkins, 2005, pp. 1-11. 
[15] K. Wilhelmus, "Epidemiology of ocular infections," in Tasman M & Jaeger EA (eds) Duane's 
clinical ophthalmology, vol.2, Philadelphia, PA, Lippincott, Williams & Wilkins, 2005, pp. 1-64. 
[16] D. Locarcher-Khorazo and B. Seeagal, Microbiology of the eye, St Louis, MO: Mosby, 1972.  


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 56 of 59 
 
[17] J. Fahmy, S. Moller, Weiss-Bentzon and M, "Bacterial flora of the normal conjunctiva II," Acta 
Ophthalmol, vol. 53, pp. 237-253, 1975.  
[18] S. Block, J. Hedrick, R. Tyler, A. Smith and e. al, "Increasing bacterial resistance in pediatric 
acute conjunctivitis," Antimicrob Agents Chemother, vol. 44, pp. 1650-1654, 2000.  
[19] R. Rietveld, G. ter Riet, P. Bindels, J. Sloos and H. vanWeert, "Predicting bacterial cause in 
infectious conjunctivitis: cohort study on informativeness of combinations of signs and 
symptoms," Br Med J, vol. 329, pp. 206-210, 2004.  
[20] N. Buznach, R. Dagan and D. Greenberg, "Clinical and bacterial conjunctivitis in children in the 
antibiotic resistance era," Pediatr Infect Dis J, vol. 24, pp. 823-828, 2005.  
[21] K. Kernt, M. Martínez, D. Bertin, D. Stroman, G. Cupp and e. al, "A clinical comparison of two 
formulations of tobramicyn 0.3% eyedrops in the treatment of acute bacterial conjunctivitis," 
Eur J Ophthalmol, vol. 15, pp. 541-549, 2005.  
[22] R. Rietveld, H. vanWert, G. TerRiet and P. Bindels, "Diagnostic impact of signs and symptoms 
in acute infectious conjunctivitis: systematic literature search," Br Med J, vol. 327, p. 789, 
2003.  
[23] A. Wall, N. Sinclair and J. Adenis, "Comparison of Fucithalmic (fusidic acid viscous eye drops 
1%) and Noroxin (norfloxacin ophthalmic solution 0.3%) in the treatment of acute bacterial 
conjunctivitis," J Drug Assess, vol. 1, pp. 549-558, 1998.  
[24] Centro Nacional de Excelencia Tecnológica en Salud, "Guía de Práctica Clínica: Diagnóstico y 
Tratamiento de Conjuntivitis en el Primer Nivel de Atención," Instituto Mexicano del Seguro 
Social, México D.F., 2015. 
[25] A. Azari and N. Barney, "Conjunctivitis: A Systematic Review of Diagnosis and Treatment," 
JAMA, vol. 310, no. 16, pp. 1721-1729, 2013.  
[26] C. Betanzos, "Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the 
gyrA and parC genes of Sthaphylococcus epidermidis strains isolated from patients with 
endophthalmitis, corneal ulcers and conjunctivitis," Ophthalmic Res, vol. 42, no. 1, pp. 43-48, 
2009.  
[27] M. R, K. LM, R. EG and K. RP., "Fourth generation fluoroquinoles: new weapons in the arsenal 
of ophthalmic antibiotics," Am J Ophthalmol, vol. 133, pp. 463-466, 2002.  
[28] A. Vora, "Pazufloxacin. Drug review," JAPI, vol. 57, pp. 722-23, 2009.  
[29] S. Minami, R. Hattori and A. Matsuda, "Pharmacological properties and expected clinical role 
of an injectable new quinolone antibiotic, pazufloxacin mesilate," Nihon Yakurigaku Zasshi, 
vol. 122, no. 2, pp. 161-178, 2003.  
[30] G. Zhanel, S. Fontaine, H. Adam, K. Schurek and e. al, "A review of new fluoroquinolones: focus 
on their use in respiratory tract infections," Treat Respir Med, vol. 5, pp. 437-465, 2006.  
[31] L. Sophia, "RESEARCH MEDICINAL INFORMATION: PRO-157 Pazufloxacino," Zapopan, 2017. 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 57 of 59 
 
[32] Sophia Laboratories, S.A. de C.V., "Preclinical comparative study on the safety and acute 
toxicity of the ophthalmic solution PRO-157 pazufloxacin prepared by Laboratorios Sophia S.A. 
de C.V. Code: PAZUVSMOGAPREEN12V1," Medical Address, Zapopan, Jalisco, 2012. 
[33] Sophia 
Laboratories, 
S.A. 
de 
C.V., 
"PRECLINICAL 
RESEARCH 
PROTOCOL 
No. 
PAZUVSMOGA0211V" COMPARATIVE STUDY OF DISTRIBUTION OF FOURTH GENERATION 
QUINOLONAS IN AQUEOUS, CORNEA AND CONJUNCTIVE HUMOR "," Dirección Médica, 
Zapopan, Jalisco., 2012. 
[34] Sophia Laboratories, S.A. de C.V., "" Phase I clinical study, to evaluate the safety and 
tolerability of the PRO157 ophthalmic solution in healthy volunteers "SOPH157-0412 / I," 
Dirección Médica, Zapopan, Jalisco, 2012. 
[35] Sophia Laboratories, S.A. de CV, "Phase II clinical study, multicenter, randomized, double 
masked to evaluate the safety and efficacy of the ophthalmic solution PRO-157 in three 
different posologies versus Moxifloxacin and versus Gatifloxacin in patients with bacterial 
conjunctivitis," Dirección Médica, Zapopan, Jalisco , 2016. 
[36] R. Fiscella, "Ophthalmic Drug Formulations," in Clinical Ocular Pharmacology, St Louis, MO, 
Butterworth Heinemann Elsevier, 2008, pp. 17-37. 
[37] N. Efron, "Grading scales for contact lens complications," Ophtalmic Physiol Opt, vol. 18, pp. 
182-186, 1998.  
[38] J. Kanski, Oftalmología Clínica, Barcelona: Elsevier, 2009.  
[39] S. Chow, J. Shao and H. Wang, Sample size calculations in clinical research. 2nd Ed., Chapman 
& Hall/CRC Biostatistics Series, 2008.  
[40] Ministry of Health Mexico, "NORMA Oficial Mexicana NOM-220-SSA1-2012, Installation and 
operation of pharmacovigilance.," Official Gazette, 2013.  
[41] International Conference on Harmanisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, "Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting E2A," ICH Harmonised Tripartite Guideline, vol. 4 version, 1994.  
[42] International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, "General Considerations for Clinical Trials," ICH Topic E8, 
1998.  
[43] I. Aramendi, L. Ardao, M. Oyarzun, M. Pérez, I. Olmos and M. Frontini, "Problemas 
relacionados con medicamentos en pacientes hospitalizados en el Hospital Vilardebó," Rev 
Psiquiatr Urug, vol. 75, no. 2, pp. 123-133, 2011.  
[44] R. Meyboom, A. Egberts, I. Edwards, Y. Hekster, F. Koning and Gribnau, "Principles of signal 
detection in pharmacovigilance.," Drug Safety, vol. 16, pp. 355-365, 1997.  
[45] A. Smith and C. Waycaster, "Estimate of direct and indirect cost of bacterial conjunctivitis in 
the United States," BMC Ophthalmol, vol. 9, no. 13, pp. 9-13, 2009.  
 
 


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 58 of 59 
 
 
 
 
 Page left intentionally blank


PRO-157 
 
Clinical study protocol: SOPH157 -0217 / III 
 
 
Version: 2 
Sophia Laboratories, S.A. of C.V.              CONFIDENTIAL                                                    Page 59 of 59 
 
12. Signature page 
12.1 Signatures of the sponsor's representatives 
First name: 
 
Dr. Leopoldo Martín Baiza Durán 
 
Title: 
Date 
Medical responsible for the study 
Firm 
 
First name: 
 
QFB. Francisco García Vélez 
 
Title: 
Date 
Director of the study 
Firm 
 
First name: 
 
Dr. Oscar Olvera Montaño 
 
Title: 
Date 
Protocol author 
Firm 
 
12.2 Investigator 
I agree to conduct this clinical study according to the design and guidelines of this protocol, abiding 
by the provisions of this protocol. I agree to conduct the study in accordance with the accepted 
standards of Good Clinical Practices. I agree to report all information or data in accordance with the 
provisions of the protocol, in particular, any adverse event. Also, I agree to handle the clinical 
supplies, provided by the sponsor, strictly in accordance with this protocol. I understand that the 
information that identifies me may be used by the sponsor. Because the information contained in 
this protocol and the Investigator's Manual is confidential, I understand that it is prohibited to share 
it with any third party, who is not involved in the approval, supervision or conduct of the study. I 
will make sure to take the necessary precautions to protect loss information, inadvertent disclosure 
or access by unauthorized third parties. 
Name: 
 
 
Firm 
Title: 
 
 
Date